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ABSTRACT 
Multiple sclerosis (MS) is a leading cause of neurological disability in 
young adults. Although current treatments can reduce symptomology and 
relapse rate, they are unable to prevent the chronic neurodegeneration that 
occurs at later stages. MS pathology is mediated by complex interactions 
between invading immune cells, neurons, glia, and endogenous stores of neural 
progenitor cells (NPCs). Factors critical to NPC/immune cell communication as 
well as the survival, differentiation, and proliferation of NPCs are not well defined. 
Elucidation of these factors will allow for the advancement of NPC transplantation 
therapies as well as the identification of novel pharmacological targets.  
Fas – a member of the tumor necrosis superfamily of death receptors – 
has diverse, cell-specific functions and is a major modulator of autoregulation 
within the immune system. Although Fas is expressed by NPCs, its exact role in 
this cell type was previously unknown. To contribute to this body of knowledge, 
the experiments in this dissertation examined the role of the Fas receptor (Fas) 
and Fas ligand (FasL) in NPC survival, differentiation, and T-cell cross-talk in 
vitro and in vivo in experimental autoimmune encephalomyelitis (EAE; a well-
established animal model of MS). 
Activation of Fas via FasL increased NPC survival by decreasing 
apoptosis (as opposed to increasing proliferation) in vitro. This decreased 
apoptosis correlates with upregulation of the inhibitor of apoptosis protein (IAP) 
Birc3. Further investigation into the importance of Fas in NPCs was 
accomplished by comparing wild-type and Fas-deficient (lpr) NPCs. Lpr NPCs 
exhibited decreased apoptosis, decreased proliferation, and increased 
differentiation to oligoprogenitor and neuronal lineages. These studies suggest 
the Fas system plays multifaceted roles in NPCs and that its exact functions are 
dependent on both functional Fas expression and presence or absence of FasL. 
To determine the role of Fas/FasL in neuroimmune cross-talk, co-cultures 
of wild-type or lpr NPCs with different T-cell subtypes (Th1, Th2, and Th17 cells) 
were performed. Th1 cells were the only subtype capable of inducing NPC 
apoptosis. Th1-mediated death was dose-dependent and was not mediated via 
Fas. On the other hand, NPCs were able to induce significant apoptosis in pro-
inflammatory Th1 and Th17 cells without affecting anti-inflammatory Th2 cells. 
NPC-induced Th17 cell death was mediated via Fas. These data suggest NPCs 
can specifically target pro-inflammatory T-cells and can promote neuroprotection 
by inducing death of these proencephalogenic cells. Finally, intravenous injection 
of wild-type or lpr NPCs into EAE mice reduced clinical symptoms and CNS 
immune infiltrate to the same extent. Few NPCs enter the CNS, where they 
remain undifferentiated. This suggests the main mechanism through which NPCs 
produce beneficial results in EAE is via peripheral immunoregulation, which is not 
dependent on Fas expression. Overall, this dissertation elucidates the Fas 
system as an important modulator of NPC cell-fate and immunoregulatory 
capacity.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
 
Introduction 
Multiple sclerosis (MS) is a chronic neurological disease - affecting a significant 
number of young adults – for which new therapies must be developed in order to 
alter the usually debilitating disease course. The pathogenesis for this disease is 
not completely understood, but autoimmune inflammatory CNS damage lead by 
T-cells reactive against myelin protein is the generally accepted hypothesis. The 
disease is mediated by various T-cell subtypes that can either tip the balance for 
or against neuronal damage. Due to the crucial role T-cells play in the 
pathogenesis of MS, immunomodulatory therapies are the main treatment 
options for patients. Though currently available treatments are somewhat helpful 
in treating disease relapses, they do not prevent the eventual accumulation of 
axonal damage and neurodegeneration that ultimately results in irreversible 
neurological damage (Myhr, 2008). Neural progenitor cell (NPC) transplantation 
has shown promising results in experimental autoimmune encephalomyelitis 
(EAE; an animal model of MS), where clinical symptoms have been significantly 
decreased or eliminated along with decreased inflammation and axonal damage 
on a histological level (Pluchino et al., 2004). Very few transplanted NPCs remain 
in the brain and terminally differentiate into oligodendrocytes or glial cells; 
however, a more pronounced function of these cells is their immunoregulatory 
and neuroprotective functions (Einstein, 2008). Since transplanted NPCs have 
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the ability to migrate to areas of brain inflammation, where they could accelerate 
remyelination by inducing growth factor production and activating endogenous 
progenitor cells, they represent a logical and innovative therapeutic approach for 
development.  
 
The long-term survival of transplanted NPCs needs to be addressed in order for 
this treatment option to be viable for a chronic human disease such as MS. One 
possible way NPC survival could be enhanced in vitro and in vivo is through 
manipulation of receptors or other factors that prevent apoptosis. Fas, a receptor 
with well known functions in the immune system but unresolved functions in the 
nervous system and NPCs in particular, may be an important therapeutic target. 
The importance of Fas/FasL in MS remains unclear because data from Fas 
manipulations in EAE have been conflicting – thus, the importance of this factor 
in NPCs and MS may need to be elucidated in a more simplified system. The 
goal of this dissertation research was to manipulate Fas in vitro, investigate its 
importance in the communication between NPCs and T-cells (a mimic of 
interactions that occur in MS CNS lesions), and consequently determine if 
modulating NPC Fas expression results in enhanced post-transplantation 
survival and more effective amelioration of EAE. 
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Multiple Sclerosis and the need for improved therapies 
 
The Disease 
MS is a chronic debilitating disease characterized by multifocal lesions of the 
white matter and a variable clinical course. It is the most common inflammatory 
demyelinating disease of the CNS, affecting more than 400,000 people in the US 
and 1.1 million worldwide (Noonan et al., 2002). MS is a major public health 
issue with a considerably high socio-economic burden. It is predominately a 
disease of young adults, and is the main non-traumatic cause of neurological 
disability in this age group (Sospedra & Martin, 2005). According to a Department 
of Health and Human Services Report (1992), the mean age of death in MS 
patients is 13 years younger than the national average. Even more striking is the 
profound decreased quality of life MS patients experience (Wynia et al., 2008). 
This decreased quality of life is related to the disabilities MS patients experience, 
including fatigue, impaired cognitive functioning, depression, and bladder and 
sexual dysfunction.  
Fatigue is often described by patients as their most disabling symptom 
(Chaudhuri & Behan, 2004a). Other common MS symptoms during relapse 
include spasticity (hypertonia), ataxia/tremor, double vision, impaired ambulation, 
pain, and mood disturbance. Any of these symptoms could persist or gradually 
worsen to long-term disability. Additionally, cognitive impairment significantly 
affects patients due to memory problems, decreased speed of information 
processing, decreased mental flexibility, and impaired executive functioning 
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(Heesen et al., 2010). Certain psychiatric illnesses (major depression, bipolar 
disorder, and psychosis) have an increased prevalence among MS patients 
compared to the general population (Cerqueira et al., 2010; Sullivan et al., 1995).   
 
MS typically progresses from a relapsing-remitting disease -characterized by 
bouts of CNS inflammation - to a chronic-progressive course, wherein the 
disease becomes more “neurodegenerative” in nature with mounting axonal 
degeneration and neuronal loss (Compston, 2008; Leray et al., 2010). These 
presentations of the disease are referred to as relapsing-remitting MS and 
secondary-progressive MS, respectively. It has been reported that progressive 
accumulation of neurological deficits results in 50% of untreated patients 
becoming wheelchair bound after 15 years (Weinshenker, 1995). This highlights 
the importance of developing treatments that can effectively combat the 
mounting axonal loss and neurogeneration that occurs in later stages of the 
disease. 
Etiology 
Though the cause of MS is still debated, the most prominent, and generally 
accepted, theory is that autoreactive T-cells directed against components of 
myelin protein cause inflammatory neurological damage. The significant clinical, 
genetic, and pathological heterogeneity of the disease indicate that developing 
MS may be dependent on multiple pathogenic mechanisms as well as complex 
interactions between genetic susceptibilities and environmental insults. The 
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genetic basis of MS appears to be uncertain, but strong evidence for a genetic 
contribution to the disease comes from family and twin studies (Stern & Keskin, 
2008). In several studies, certain genetic “risk factors” such as polymorphisms in 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene and the human leukocyte 
antigen (HLA)-DRB1 haplotype on chromosome 6 have been implicated in 
conferring susceptibility to MS (Stern & Keskin, 2008). 
 
Studies have also implicated various environmental factors that may contribute to 
susceptibility and disease development (summarized in Table 1). Geographic 
differences appear to be important, as the risk of developing MS increases from 
south to north (Ebers, 2008). Some of these differences could be contributed to 
ethnicity and genetic factors; however, latitude remains the strongest factor for 
risk after controlling for other variables (Wallin et al., 2004). Sunlight exposure 
and consequent active Vitamin D levels could contribute to the association 
between latitude and MS incidence. There is strong evidence for Vitamin D 
conferring protection against MS. High dietary consumption of Vitamin D (fatty 
seafood, cod liver oil, ect) or vitamin D supplementation are both associated with 
decreased risk of developing MS (Kampman & Brustad, 2008; Kassandra et al., 
2006; Munger et al., 2004).  
 
Exposure to certain pathogens as well as metabolic disturbances are suspected 
of initiating MS in susceptible individuals (Chaudhuri & Behan, 2004b; Serafini et 
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al., 2007). There is some support for Epstein-Barr virus (EBV) as an 
environmental insult that could contribute to MS development in genetically 
predisposed people. For example, a higher percentage of MS patients (>99%) 
test positive for EBV infection compared to controls (>94%) (Ascherio et al., 
2001). Though this difference is not particularly striking, the level of EBV 
antibodies in the blood appears to be important as high titers of EBV antibodies 
confers risk of developing MS (Levin & Danesh-Meyer, 2008; Sundström et al., 
2004). Smoking is a significant risk factor for MS development, and this risk has 
been shown to be dose-dependent (Hawkes, 2007; Hernán et al, 2001). In a 
study of patients diagnosed with clinically isolated syndrome, 75% of smokers 
developed MS while only 51% non smokers developed MS after 3 years (Di Pauli 
et al., 2008). 
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Table 1-1: Summary of factors that confer protection against or risk for 
developing MS 
*Adapted from Ramagoplan et al., 2010. 
Family history/genetic risk factors
Female sex
Born in high lattitude regions
Exposure to EBV
Smoking
Vitamin D deficiency
Resident in high latitude regions
Outdoor activity/sun exposure
Vitamin D supplements
Diet high in fish oils
Protective HLA haplotypes
Static Factors Dynamic Factors
P
ro
te
ct
iv
e
R
is
k 
Fa
ct
o
rs
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The most abundant and compelling data supports an inflammatory autoimmune 
process as the major source of pathology in MS. For example, inflammatory 
immune cell infiltrates are present in histopathologic MS lesion specimens from 
patient autopsies and biopsies (Lucchinetti et al., 2000), the cerebrospinal fluid of 
patients with MS have increased oligoclonal IgM and IgG levels compared to 
age-matched controls (Link 1987; Villar et al., 2005), T-cells reactive against 
myelin have been documented in the brain lesions, cerebral spinal fluid (CSF), 
and peripheral circulation of patients with MS (Oksenberg et al., 1993; Zhang et 
al., 1994). Additional support for an autoimmune basis of MS comes from studies 
that show patients with MS are more likely to have other autoimmune disorders 
compared to controls; also,  MS - like all other autoimmune diseases - affects 
more women than men with a ratio of 1.77 to 1.00. Furthermore, MS lesions 
show expression of IL-12, IL-18, and IFN-γ, all of which are markers of pro-
inflammatory T-cell (Th1) activation (Frohman, 2006). A newer line of evidence 
suggests certain polymorphisms of the gene encoding IL-7 receptor α -- a 
cytokine receptor involved in the differentiation and maintenance of B- and T-
cells -- confer risk for developing MS (Gregory et al., 2007; Lundmark et al., 
2007). Therefore, it appears that immune cells and their modulation play a crucial 
role in the pathogenesis of MS. Perhaps one of the most convincing arguments 
for an autoimmune/inflammatory cell basis of MS comes from the fact that each 
of the currently used clinical drugs work by modulating the immune system.   
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Current Therapies 
All currently available MS therapies exert their effects via immunomodulatory or 
immunosuppressive functions. They exhibit efficacy in decreasing the number 
relapses, but are unable to prevent or reverse the accumulation of neuronal cell 
death and axonal degeneration that results in neurological disability in primary 
and secondary progressive forms of the disease. The first FDA approved drug for 
MS was IFN-β1b (Betaseron). Other IFN-β preparations are Avonex and Rebif. 
The IFN-β drugs are cytokines with the ability to modulate immune 
responsiveness, but the precise mechanism of action is not well understood 
(Galetta et al., 2002).  Another immunomodulatory treatment, glatiramer acetate, 
has the ability to shift active T-cell response from the inflammatory Th1 to the 
regulatory Th2 phenotype (Steinman, 2005).   
 
Unfortunately, these therapies do not benefit all patients. Long-term studies have 
shown IFN-β and glatiramer acetate are only able to reduce the rate of relapse 
by 30% (Steinman, 2005). Natalizumab (monoclonal antibody to α4β1 integrin) 
interferes with leukocyte adherence to endothelial cells, effectively blocking the 
trafficking of pro-inflammatory infiltrates across the blood brain barrier (Myhr, 
2008). Use of this drug is controversial and restrained because of multiple cases 
of patients developing progressive multifocal leukoencephalopathy (Stüve & 
Bennett, 2007). Lastly, novantrone (mitoxantrone) suppresses the production of 
pro-inflammatory cytokines and the proliferation lymphocytes and macrophages 
(Myhr, 2008). A substantial number of patients require addition of an 
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immunosuppressant (mitoxantrone) along with their primary treatment because 
of continued relapses and disease progression. 
 
Overall, the drugs that are currently used have one mode of function (peripheral 
immunoregulation), are only useful in relapsing-remitting forms of disease, and 
do not prevent long-term disability. There are several novel agents in 
development for oral administration (as opposed to above mentioned therapies 
which are all parenteral); however, they also target different aspects of the 
immune system such as proliferation (Cladribine) or cell trafficking (Fingolimod) 
(Krieger, 2011). There is a dire need for developing therapeutics that can directly 
influence the CNS. Methods of enhancing remyelination and decreasing axonal 
damage (i.e. promoting neuroprotection) will be particularly useful later stages 
and primary progressive MS – forms of the disease which are notoriously 
resistant to immunotherapies.    
 
Important immune components and concepts in MS  
 
The Road to Damaged Myelin 
Exact mechanisms contributing to MS pathology are still debated; particularly the 
exact trigger/antigen leading to CNS inflammation remains most elusive. Despite 
this, considerable data, both from the EAE murine model and from patient data 
supports the following sequence of events contributing to inflammatory infiltration 
and CNS tissue damage (See Figure 1-1 illustrating each step).  
11 
  
 
Figure 1-1: Cascade of events leading to CNS damage     
T-cells are activated in the periphery by an antigen presenting cell. Autoreactive 
T-cells then enter the CNS where they are re-activated and damage the myelin 
sheath, exposing neurons to damage, via a variety of mechanisms. Inflammation 
is propagated by production of chemokines that recruit additional immune cells to 
infiltrate the CNS compartment. Figure courtesy of Dr. Hillel Panitch. 
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Peripheral activation (Figure 1-1(1)) of an autoreactive T-cell is considered the 
first step. This may occur via a “molecular mimicry” process, where an invading 
antigen is similar to a CNS self antigen, causing cross-reactivity. Support for one 
specific instigating antigen is lacking, and it has been proposed that the antigen 
may actually be different in different individuals or change over the course of time 
in one individual and this may contribute to the heterogeneity that exists within 
MS. However, there is strong evidence that the antigen is myelin-related. For 
example, a study using altered peptide ligands (APLs) met with unexpected 
results in clinical trials. Myelin basic protein 83-99 (MBP83-99) was originally 
developed in EAE as a therapeutic. It was hypothesized to work by interacting 
with the T-cell receptor and reducing the activation of autoreactive T-cells while 
increasing the production of regulatory T-cell populations. Phase II clinical trials 
of this drug were shut-down due to reports of exacerbation of MS symptoms and 
clinical relapse (Martin, 2000). These relapses were preceded by expansion and 
activation of MPB-specific CD4+ T-cells in the periphery (Martin, 2000). 
Additionally EAE, a model disease induced in animals by injection of various 
myelin derivatives, shares important pathological and clinical parallels with MS 
(Wekerle, 2008). These provide convincing evidence that immune autoreactivity 
to myelin is involved in the pathogenesis of MS.  
 
A peripherally activated T-cell enters the CNS by first adhering to the endothelial 
BBB (Figure 1-1(2)). This process occurs via a “rolling” and “tethering” process 
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mediated by selectins and integrins. Endothelial cells in MS lesions express 
higher levels of the adhesion molecules intracellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule (VCAM)-1, and levels correlate with extent 
of immune infiltration (Cannella & Raine, 1995; Ransohoff, 1999; Washington et 
al., 1994). Their cognate ligands (lymphocyte function-associated antigen [LFA]-1 
and very late antigen [VLA]-4) are found on perivascular inflammatory cells (Bö 
et al., 1996). Local production of lytic enzymes (i.e. matrix metalloprotenases 
[MMPs]) facilitates breakdown of the basement membrane and allows immune 
cells to infiltrate the brain parenchyma (Kieseier et al., 1999)(Figure 1-1(3)). 
 
Once the autoreactive T-cell has invaded the CNS, it is reactivated (Figure 1-
1(4)) by an antigen presenting cell (microglia or astrocyte). The entire process 
culminates in direct or indirect damage to neurons and oligodendrocytes (Figure 
1-1(5)). Myelin sheath destruction leads to transected axons, and ultimately 
clinical symptomology in patients. A variety of mechanisms are implicated in CNS 
tissue damage, including proinflammatory cytokines, NO-/reactive oxygen 
species, glutamate-mediated cytotoxicity, complement fixation, and MMPs (Bar-
Or, 2008). Inflammation-driven tissue damage is perpetuated by production of 
chemokines that attract additional infiltrating cells (Figure 1-1(6)). The chemokine 
CCL5/RANTES is upregulated at the MS lesion edge (Hvas et al., 1997) and 
CCR2 is expressed by local astrocytes (Tanuma et al., 2006). Futhermore, the 
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CSF of MS patients contains elevated levels of CXCL10 and CCL5 (Nakajima et 
al., 2004; Szczucinski, 2011). 
Mediators of Inflammation and Regulation 
Just as current MS therapy targets specific immune cells in acute inflammation, 
treatment for chronic lesions will have to address specific subpopulations of T-
cells. Both CD8+ and CD4+ T-cells are visualized in acute inflammatory lesions 
and to a lesser extent in chronic demyelinated lesions (Stadelmann & Brück, 
2008). CD4+ and CD8+ T-cells are activated by major histocompatibility complex 
type II (MHC-II) and MHC-I molecules, respectively. Based on several genetic 
risk studies, MHC-II alleles confer the largest risk for MS (Oksenberg & Hauser, 
2005). Furthermore, CD4+ T cells are the main mediators of MS pathogenesis 
(Bar-Or, 2008; Lutton et al., 2004). Therefore, I focus on CD4+ T-cell subsets in 
my study.  
 
Naïve CD4+ T-cells differentiate into 4 distinct subsets: Th1, Th17, Th2, and Treg 
(illustrated in Figure 1-2). This differentiation is highly dependent on the cytokine 
milieu (Dittel, 2008). For instance, IL-12 is required to produce Th1 cells, while 
the presence of IL-4 is needed for Th2 cells. TGF-beta is essential for the 
generation of both Treg and Th17 cells, but the addition of IL-6 is needed for 
creating Th17 cells.  Exposure to different cytokines leads to the expression of 
transcription factors specific to each respective lineage (Figure 1-2).  
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Figure 1-2: The major CD4+ Subtypes 
Upon appropriate stimulation (often CD3/CD28), a naïve T-cell differentiates into 
one of several subsets, dictated by the cytokine milleu. Shown are cytokines 
required for production of each subset. Each CD4+ subtype is characterized by 
the cytokines they produce. Cells producing anti-inflammatory cytokines are 
shown in GREEN and those producing pro-inflammatory cytokines are shown in 
RED. To further differentiate these cells, each subtype also has unique 
expression of transcription factors (shown below each cell type within the “cell”).  
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Furthermore, these T-cell subtypes are categorized by the type of cytokines they 
produce (Hedegaard, 2008). Th1 cells are characterized by production of IFN-
gamma and TNF-alpha (pro-inflammatory), while Th2 cells manufacture IL-4 
(anti-inflammatory). 
 
Th1 and Th-17 cells are most likely the main inducers of disease activity 
(McFarland & Martin, 2007). Production of IFN-γ by Th1 cells and IL-17 by Th17 
cells are thought to be the main mediators of autoimmune destruction in MS 
(McFarland & Martin, 2007). One of the functions of IFN-γ is the activation of pro-
inflammatory macrophages which drive chronic inflammation and tissue injury. 
Immunohistological investigations of CNS tissues at the height of disease in 
animal models show high levels of TNF-alpha and IFN-gamma (Khoury et al., 
1992). Comparatively, levels of these factors are relatively low in recovery 
stages. Furthermore, transfer of reactive Th1 cells alone is sufficient to induce 
EAE (Baron et al., 1993; van der Veen et al., 1993). Because of this evidence, 
dysregulated Th1 functions have been historically viewed as responsible for the 
autoimmune damage that occurs in MS. However, studies showing mice 
genetically deficient in IFN-γ not only develop EAE, but exhibit a more severe 
disease course (Ferber et al., 1996) seriously challenged this established 
concept.  
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The importance of Th17 cells in MS pathogenesis has more recently been 
appreciated (Aranami & Yamamura, 2008), and knowledge of this subtype has 
filled critical holes in MS immunological dogma. These cells produce IL-17, a pro-
inflammatory cytokine that induces the production of chemokines and 
metalloproteinases which promote propagation of inflammation and tissue 
damage, respectively. IL-17 is clearly important in EAE pathogenesis because 
mice deficient in this cytokine have an attenuated disease course (Komiyama et 
al., 2006). Likewise, administering antibodies against IL-17 helps prevent 
development of disease and delays onset of paralysis upon EAE induction (Park 
et al., 2005). Moreover, elevated IL-17 levels are found in the blood, CSF, and 
active lesions of MS patients (Matusevicius et al., 1999; Tzartos et al., 2008). 
 
Studies of IL-23 help solidify the importance of the Th17 subtype in MS 
pathogensis. IL-23 is required as a growth and maturation factor of pathogenic 
Th17 cells (McGeachy & Cua, 2007). IL-23 has a unique p19 subunit and shares 
the p20 subunit with IL-12 (required for Th1 maturation); however, genetic 
manipulation of these two genes in EAE produces very different results. IL-23p19 
deficient mice are completely resistant to developing EAE, whereas mice 
deficient in IL12 are susceptible (Cua et al., 2003). Highlighting the importance of 
IL-23, its production is higher in dendritic cells from MS patients compared to 
healthy controls (Vaknin-Dembinsky et al., 2006). Furthermore, IL-23p19 is 
expressed in both active and chronic lesions (Li et al., 2007).These findings 
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suggest IL-23 is pivotal in augmenting the inflammatory response and 
consequently contributes to CNS damage. Finally, IL-6 (another cytokine critical 
to Th17 production) gene transcripts are higher in the brain tissue of MS patients 
(Lock, 2002) and treatment with an IL-6R antibody ameliorates EAE (Serada et 
al., 2008). 
 
Both Th2 and Treg cells are thought to have overall protective roles in MS. Th2 
cells are regarded as beneficial in the context of MS lesions and play a protective 
role in EAE (Liblau et al.,1995). For example, IL-4 secreted by Th2 cells prevents 
re-induction of active EAE in recently recovered animals and Th2 cells perform 
as robust inhibitors of encephalitogenic Th1 cells in vitro (Liblau, et al., 1995; van 
der Veen, et al., 1993). The extent of inflammation in MS is controlled by the up- 
and down-regulation of CD4+ cells (Dittel, 2008). Specifically, Treg cells have the 
ability to suppress the functions of other T-cells, down-modulate inflammation, 
and protect brain tissue in this process by balancing CD4+ Th1 and Th2 subtypes 
(Dittel, 2008). Deficiency of Treg cells predisposes animals to developing organ-
specific autoimmune disease (Thornton & Shevach, 2000). Treg cells exert some 
of their anti-inflammatory effects via production of IL-10 (also produced by Th2 
cells), which has the ability to regulate the expression of cytokines and antigen 
presentation molecules (Selvaraj & Geiger, 2008; Stern et al., 2008). Studies in 
EAE suggest IL-10 protects against compromise of blood brain barrier (Dittel, 
2008). On a clinical level, T-cell cultures from MS patients in remission produce 
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higher amounts of IL-10 relative to either MS patients in relapse or healthy 
controls (Correale et al., 1995). Other mechanism for Treg inhibition of reactive 
T-cells includes cytotoxic T-lymphocyte antigen-4 expression, TGF-beta 
production, costimulatory molecule blockade and direct T-cell interactions 
(Shevach et al., 2001). Passive transfer of Treg cells protects against EAE 
whereas deletion of CD25+ Treg cells increases the severity of EAE (McGeachy 
et al., 2005; Yu et al., 2005). Levels of Treg cells are equivalent in MS patients 
and healthy controls, but the ability of MS patients’ Treg cells to inhibit myelin-
responsive inflammation is reduced (Haas et al., 2005; Venken et al., 2008). 
Thus, Treg functions are clearly important in down modulating inflammation and 
consequently mediating clinical remission. 
 
Treg cells function to control a delicate balance between avoiding autoimmune 
disease and allowing overt autoinflammatory responses, apparently required for 
promoting neuroprotection and repair, to occur. For instance, in rats with induced 
optic nerve or spinal cord damage, lack of Treg cells serves to enhance 
spontaneous T-cell inflammatory responses and consequent post-injury neuronal 
survival; however, increasing the number of Treg cells has an opposite “pro-
neuronal injury” effect (Kipnis et al., 2002).  So, Treg cells are very efficacious at 
decreasing the inflammatory processes that lead to damage in MS, but excess 
numbers of Treg cells may actually prevent inflammation-mediated brain repair. 
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Neuroprotective Autoimmunity 
In general, it is thought that inflammatory processes in the brain are detrimental; 
however, recent evidence suggests autoimmune inflammation can promote CNS 
protection and repair processes like remyelination (Kerschensteiner et al, 2003). 
This concept of “neuroprotective autoimmunity” is important to consider in the 
pathogenesis of MS since autoimmune processes, which clearly play a role in 
initiation of the disease process, also have the potential to be beneficial and 
decrease neuronal injury. 
 
There are several lines of evidence that support the idea that inflammation after 
CNS injury can have beneficial side-effects. In rodents, the transfer of myelin-
reactive T-cells reduces post-injury neuronal loss relative to controls (Butovsky et 
al., 2001; Hauben et al., 2000; Moalem et al., 2000). For example, in optic nerve 
crush injury experiments, secondary degeneration of neurons is decreased when 
animals are treated with T-cells directed against myelin epitopes (Moalem et al., 
1999; Schwartz et al, 1999). Importantly, immunodeficient animals have 
diminished capacity to recover from damage to the nervous system (Serpe et 
al.,1999; Serpe et al., 2002). Furthermore, animals lacking endogenous T-cells 
suffer worse CNS injury compared to wild-type animals (Kipnis et al., 2001; Yoles 
et al., 2001). In a mouse model of lysolecithin-induced demyelination, Rag-1-
deficient mice (CD4+ and CD8+ depleted) fail to remyelinate (Beiber, 2003), thus 
supporting the view that functional T-cells are central to remyelination processes. 
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The exact mechanism for how inflammatory cells can mediate neuroprotection 
remains to be discovered. One possible way of facilitating this process could be 
through the production of neurotrophic factors. Immune cells are known to 
produce both BDNF (shown to be expressed in inflammatory brain lesions of MS 
patients) and NGF (Kerschensteiner, et al., 2003). Myelin-reactive T-cells home 
to sites of injury and have been implicated in upregulating the production of 
GDNF, NGF, NT3 and anti-thrombin III (Schwartz, 2001). 
 
The factors important in regulating a dual or “two-faced” role of autoimmunity -- 
where autoimmune inflammation is responsible for significant tissue damage, but 
is also required for repair processes occur -- are only beginning to be defined. As 
an example of the dichotomous role of immunity, IFN-γ is undoubtedly a major 
player in destructive inflammatory processes, but this cytokine also enhances 
microglial clearance of glutamate in response to damage – a necessary step in 
repair processes (Shaked et al., 2005).  
 
Introduction of exogenous NPCs to inflammatory lesions have shown potential 
for promoting the beneficial effects of the immune response. For example, 
transplanted adult NPCs and inflammatory cells (T-cells and microglia) work 
synergistically to promote neurogenesis and functional recovery in spinal cord 
injury (Ziv et al., 2006). Moreover, NPC transplantation has the ability to reduce 
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the number of pro-inflammatory T-cell perivascular infiltrates and increase the 
proportion of Treg cells (Einstein et al., 2006), thus in two respects they can 
function to down-regulate inflammation. Elucidating the effects of separate T-cell 
populations on NPCs is important in the context of transplantation therapies as 
well as promotion of remyelination by endogenous oligo- and glial- progenitors 
that reside in the CNS.  
 
Progress and Promise of Neural Stem Cell Therapies  
NPCs are a heterogeneous population of self-renewing and multipotent cells 
(Martino & Pluchino, 2006). They can proliferate almost indefinitely in serum-free 
cultures supplemented with EGF and FGF, but when growth factors are 
withdrawn, they will spontaneously differentiate into neurons, astrocytes, or 
oligodendrocytes (post-mitotic daughter cells) (Galli et al., 2003). In suspension, 
NPCs form characteristic free-floating neurospheres (non-adherent spherical 
aggregates of cells), but they can also be grown as proliferating single cells in a 
supporting matrix monolayer (Galli et al., 2003). At the beginning of the 20th 
century, the observations of Cajal lead him to distinguish between the developing 
and mature CNS on the basis of the adult CNS lacking the ability to regenerate 
(Cajal, 1928). However, he did speculate there was some limited capacity for 
regeneration. For the majority of the 20th century, it was thought that the adult 
CNS was static, and any brain injury would be doomed to persist without repair. 
In the late 1960s, the observation of proliferating neural cells in the adult rat brain 
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made the possibility of CNS regeneration more feasible (Altman, 1969; Altman & 
Das, 1965). It is now recognized that neural stem/progenitor cells reside in the 
adult CNS and support neurogenesis and gliogenesis throughout life (Reynolds 
and Weiss, 1992; Pluchino & Martino, 2008). NPCs reside in definitive 
germinative zones in the developing and adult CNS and as such they can be 
isolated from embryonic, fetal or adult tissues (Martino & Pluchino, 2006). The 
main niches of NPCs in the adult are the subventricular zone (SVZ) of the lateral 
ventricles and the subgranular zone of the hippocampal dentate gyrus (Pluchino 
& Martino, 2008).  
 
Though remyelination occurs throughout the course of MS, ultimately the 
endogenous supply of NPCs fails to promote full and long-lasting repair (Pluchino 
et al., 2004).This may be due to a derangement of normal sub-ventricular zone 
progenitor cell proliferation and differentiation by inflammation (Pluchino & 
Martino, 2008).  A possible mechanism for this disruption of normal NPC 
physiology could be the production of stem cell regulators – such as BMP4 or 
noggin – and/or cytokines from infiltrating immune cells and reactive CNS-
resident cells (astrocytes, microglia, and brain endothelial cells). Support for this 
theory comes from observations that overall remyelination in periventricular 
regions – the main location of inflammatory CNS lesions in MS - is lower than 
other brain areas (Patrikios et al., 2006) and areas of demyelination contain 
oligodendrocyte precursors without signs of remyelination (Chang et al., 2002). 
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Inadequate remyelination leaves axons susceptible to injury or elimination in the 
destructive MS lesion environment. Since axonal damage is one of the most 
important pathological events related to neurological disability in MS, developing 
methods to protect axons by enhancing remyelination is a major direction of 
current research.  Transplantation of cells with neuroprotective potential into the 
damaged adult CNS provides possibility for bypassing the limited capacities of 
endogenous cells. Furthermore, since inflammation likely disrupts the structural 
and functional integrity of progenitor germinal centers in the brain, introducing 
exogenous NPCs in MS may be more efficacious than protocols aimed at 
activating endogenous stores of NPCs.  
 
The development of neural stem cell transplantation therapy holds potential for 
many neurodegenerative diseases for which there is no currently effective 
treatment – the paradigmatic disease being MS (Pluchino & Martino, 2005; 
Rosser et al., 2007). Multiple groups have concluded that transplanting NPCs 
into EAE animals results in reduction of inflammation, decreased demyelination 
and axonal damage, and consequent improved clinical outcomes (Einstein et al., 
2003; Pluchino et al., 2003; Politi et al., 2007). Clear therapeutic effects were 
observed in both chronic-progressive and relapsing-remitting EAE. Intravenously 
and intraventricularly injected NPC are able to migrate specifically to inflamed 
areas of the CNS (Pluchino, et al., 2003). Acute inflammatory lesions attract and 
maintain transplanted cells, allowing for NPC to exert their neuroprotective 
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effects (Ben-Hur et al., 2003). This homing is due to NPC expression of high-
affinity cell adhesion molecules (such as CD44, VLA-4) and functional chemokine 
receptors, which allow them to utilize the same pathways that immune cells travel 
when invading the inflamed CNS (Pluchino & Martino, 2005). With expression of 
these molecules, NPCs are able to follow a cytokine gradient -- in either CSF or 
blood – that leads them to sites of CNS inflammation. Highlighting the importance 
of these mechanisms, when NPCs are pre-treated with VLA-4 neutralizing 
antibody before transplanting, only 5% of transplanted NPC home to inflamed 
regions of the CNS (Pluchino et al., 2005). 
 
Though originally pursued as a cell-replacement strategy, transplanted NPCs 
appear to exert their therapeutic effects mostly through bystander 
neuroprotective and immunoregulatory functions. I will discuss the 
neuroprotective bystander functions of NPCs here, and cover their robust 
immunomodulatory capacity in the next section (“The neuro-immune interface”). 
Most transplanted cells retain an undifferentiated phenotype, so it is rare for them 
to terminally differentiate and replace lost neural cells. Pluchino’s work showed 
only 10-15% of injected NPCs became positive for oligodendrocytes markers 
(Pluchino et al., 2003); therefore, most remyelination that occurs in these EAE 
transplant models must be carried out by endogenous cells. Transplanted NPCs 
appear to exert their neuroprotective effects via a bystander mechanism wherein 
released neurotrophic factors (NGF, BDNF) facilitate endogenous neuronal 
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health (Martino & Pluchino, 2006). Specifically, transplanted NPCs can foster 
remyelination driven by endogenous oligodendrocytes and decrease astrogliosis. 
Furthermore, neurotrophic factors released by NPC promote axon growth when 
introduced into a co-culture system with dissected brain cortex and spinal cord 
(Kamei et al., 2007).  
 
A major issue in transplantation therapy is the long-term survival of stem cells in 
the adult CNS. Individual precursor cells do not survive well in the adult brain, 
presumably because levels of required growth and trophic factors, such as 
epidermal growth factor (EGF) and fibroblast growth factor (FGF), are not 
sufficient (Einstein et al., 2006). In vivo survival of NPCs is drastically improved in 
the EAE model when transplanted as neurospheres. Neurospheres grown from 
adult NPCs can survive for up to 2 months in the CSF of mice, possibly because 
of their ability to create a self-sustaining microenvironment by producing trophic 
signals (Einstein et al., 2006). However, the longer term survival of neurospheres 
is as yet unknown. Because of their large size and heterogeneous makeup, 
translation into humans may be more difficult than dissociated single-cell 
therapies. In rat models, oligodendrocyte precursor cells are unable to survive 
upon transplantation into a healthy/normal CNS environment (Franklin et al.,  
1996; O'Leary & Blakemore, 1997). However, survival of OPCs is dramatically 
improved when transplanted during an active inflammatory process (Tourbah et 
al., 1997). It has been further established that acute lesions can both attract and 
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prolong survival of transplanted cells (Ben-Hur et al., 2003; McDonald et al., 
1999; Modo et al., 2002). In chronic diseases, such as MS, transplanted cells 
would need to survive during both remission and relapsing stages of the disease 
in order to be an effective treatment. Therefore, elucidating strategies for 
promoting NPC survival in a growth factor-poor environment is critical for 
advancing transplantation therapies. The exact mechanisms responsible for 
increased progenitor cell survival in the presence of inflammation remain 
unknown.  
 
The neuro-immune interface 
It is well established that one of the main effects that transplanted NPCs exert is 
“bystander” immunomodulation (Ben-Hur, 2008; Einstein & Ben-Hur, 2008; 
Fainstein et al., 2008; Pluchino & Martino, 2008). However, the exact factors that 
contribute to NPC immunomodulatory capacity are unknown.  Considering that 
the interactions between immune cells and NPCs (among other resident CNS 
cells) is critical in both pathology and repair processes in MS, a full 
understanding of the critical pathways that influence NPC/T-cell interactions is 
important for developing novel therapies.  
 
Places of possible interaction for these cell types include the CNS and the 
periphery. As mentioned above, injected NPCs have the ability to home to sites 
of CNS inflammation where they can modulate inflammation and repair 
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processes directly. Injected NPCs reduce CNS inflammation, axonal injury, and 
demyelination. One of the ways NPCs down-modulate inflammation, and 
consequently reduce CNS tissue damage, is by inducing pro-inflammatory Th1 
cell apoptosis (Pluchino et al., 2005). Transplantation of adult NPCs into EAE 
mice significantly decreased the number of inflammatory CNS infiltrates and 
increased the number of TUNEL positive encephalitogenic T-cells by 3-fold. 
These effects are attributed to upregulation of death receptor ligands (FasL, Trail, 
and APO3) on NPCs upon exposure to pro-inflammatory cytokines produced by 
Th1 cells. Furthermore, blockade of the death receptor pathways significantly 
decreased the in vivo and in vitro apoptosis of reactive Th1 cells. Therefore, 
NPC-induced Th1 cell death mediated via death receptors such as Fas helps 
shift toward a more favorable Th2 dominated environment; thus, resulting in 
reduced brain inflammation (Pluchino et al., 2005). It has also been shown that 
NPCs inhibit T-cell proliferation by both producing and inducing T-cell up-
regulation of NO and prostaglandin E2 (Wang et al., 2009). 
 
In addition to central effects, intravenously administered NPCs can interact with 
T-cells in lymph nodes and help attenuate EAE by decreasing peripheral T-cell 
activation (Einstein et al., 2007; Pluchino et al., 2009). Co-culture experiments 
showed NPCs have the ability to inhibit lymph node derived T-cell proliferation in 
response to either polyclonal or CNS-derived antigens (Einstein, et al., 2007). 
EAE mice injected subcutaneously with NPCs (in order to target lymph nodes) 
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show significant clinical improvement compared to controls (Pluchino et al.,  
2009). These results are similar for mice injected either intravenously or 
intraventricularly. Subcutaneously injected NPCs are able to modulate EAE by 
inhibiting the activation of myeloid dendritic cells as well as hindering the 
expansion of encephalogenic T-cells (Pluchino et al., 2009). Further supporting 
the peripheral immuoregulatory role of NPCs, human NPCs transplanted into a 
primate EAE model inhibited dendritic cell activation and presentation as well as 
reduced IFNγ production (Pluchino et al., 2009). Though the immunomodulatory 
capacity of NPCs is clear, the exact mechanisms regarding process are just 
beginning to be uncovered. Elucidating the factors important in NPC-mediated 
immunoregulation is a critical step toward advancing NPC transplantation 
therapies.  
 
Additionally, specific T-cell influences on NPC -- which I propose to investigate -- 
have not yet been uncovered.  Data on the ability of T-cells to directly influence 
NPCs is rare in the literature. Repeated bouts of inflammation can alter 
endogenous NPC niche architecture and the ability of NPCs to migrate in vivo 
(Pluchino et al., 2008), and pro-inflammatory cytokines inhibit NPC proliferation 
in vitro (Ben-Hur, et al., 2003). These reports are limited to the general capacity 
of an inflammatory environment to modulated NPCs, and do not decipher direct 
effects of T-cells themselves, or difference between T-cell subtypes. My 
dissertation focuses on these unanswered questions. Therefore, my research 
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complements and expands upon previous studies that have focused on the 
ability of NPC to modulate immune cells. Overall, keeping in mind that neural-
immune communication is a two-way street will contribute to a more thorough 
understanding of MS pathogensis and new therapeutic targets. 
 
The Fas system: known, unknown, and debated 
Fas - also known as Apo-1 or CD95 - is a member of the tumor necrosis factor 
(TNF) receptor superfamily. Fas has served as a paradigmatic death-receptor for 
elucidation of cell death-induction via the extrinsic pathway (Krammer, 2000). 
Therefore, the pathway and regulation of Fas-induced apoptosis is fairly well 
characterized.  Activation of Fas via its cognate ligand, FasL, results in 
oligimerization of the receptor and assembly of the death inducing signaling 
complex (DISC) (Wajant, 2002). Contained in the DISC is Fas-associated death 
domain protein (FADD) and caspase-8. Proteolytic activity of the DISC complex 
results in the activation of caspase-8, which consequently activates (either 
directly or indirectly, depending on the type of cell) caspase-3, the effector 
caspase. The main regulatory molecule of this pathway is FLIP (FADD-like 
interleukin-1β-converting enzyme (FLICE)-like inhibitory protein). FLIP can be 
incorporated into the DISC and disable the processing and release of caspase-8 
(Peter & Krammer, 2003). The transcription of FasL itself, which is inactive in 
most cells, is another way that Fas/FasL effects are regulated. Though Fas is an 
ubiquitous receptor, T-cells are the major expressors of FasL (Wajant, 2002).  
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Fas is a well characterized death-inducer in the immune system (Krammer, 2000; 
Nagata & Golstein, 1995), wherein homeostasis (e.g. elimination of autoreactive 
T-cells) is maintained via Fas-mediated apoptosis– yet, multiple studies indicate 
this receptor has cell-specific effects that are unrelated to cell death. In fact, even 
within the immune system, the functions of this receptor seem to be diverse 
given that Fas-mediated proliferation and activation of T-cells has been reported 
(Alderson et al., 1993; Siegel et al., 2000; Wajant et al., 2003). As an example of 
the heterogeneous, non-immune functions of this receptor, human brain 
endothelial cells are resistant to FasL-induced cell death and triggering the 
receptor induces release of matrix metalloproteinase-9 (Wosik et al., 2007). 
Furthermore, several studies have indicated that the Fas-mediated cell death 
pathway is not operational in NPCs (Brunlid et al., 2007; Ceccatelli et al., 2004; 
Tamm et al., 2004). Specifically, Ceccatelli’s group found that NPCs undergo 
mitochondrial-mediated cell death in response to oxidative stress, while treating 
cells with an agonistic Fas monoclonal antibody did not induce apoptosis. 
Primary adult NPCs isolated from the subventricular zone of rat brains and a 
neural stem cell line C17.2 were used in these studies (Ceccatelli et al., 2004). 
Similarly, exposing immature and neurally differentiated murine embryonic stem 
cells to soluble FasL did not induce apoptosis (Brunlid et al., 2007). Although it 
has been previously reported that NPCs express the Fas receptor, and that 
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activation does not result in apoptosis (Ceccatelli et al., 2002), the exact roles of 
Fas in NPC biology has not been elucidated.  
 
It is possible that the role of Fas changes depending on the developmental stage 
and proliferative properties of neurons and stem cells. For example, Fas plays a 
critical role in regulating programmed cell death during embryonic development 
of the nervous system because of its expression during critical periods of 
neuronal apoptosis and differentiation (Cheema et al., 1999; C. Park et al., 1998; 
Raoul et al., 1999). Also, studies have shown Fas is involved in developmental 
neuronal death in both motor neurons (Nat et al., 2001) and cortical neurons (van 
Landeghem et al., 2002). However, Fas can mediate proliferation and 
regeneration of primary sensory (dorsal root ganglion) neurons by activating 
extracellular-signal related kinase (ERK) and upregulation of p35 (Desbarats et 
al., 2003). Further characterizing the role of this system in neuronal development, 
Fas appears to regulate neuronal branching in hippocampal neurons since mice 
deficient in Fas or FasL have a normal neuronal number, but exhibit decreased 
dendritic branching in hippocampal pyramidal cells (Zuliani et al., 2006). Thus, 
Fas appears to have an important and multifaceted role in neuronal 
development. Different from Ceccatelli’s observations mentioned above, one 
study found that Fas activation - using a monoclonal antibody to Fas - induced 
apoptosis in NPCs isolated from 15 day-old mouse embryos (Semont et al., 
2004). These results appear contrary to studies demonstrating that a Fas-
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dependent apoptosis pathway is not functional in various types of neural stem 
cells. Although the reasons for these differences are unclear, they may be related 
to the original cell source, capacities of ESCs compared to NPCs (e.g. pluripotent 
versus multipotent), culture maintenance and/or treatment conditions. 
Furthermore, Fas may play an evolving, pluripotency-dependent role in 
maintenance of the CNS. 
 
EAE: the perfect imperfect model to examine the role of Fas in Multiple 
Sclerosis 
As with other diseases, an animal model is required to elucidate important factors 
that contribute to MS pathogenesis, and thus determine therapeutic targets. EAE, 
first described over 70 years ago, is the most well-established and studied animal 
model of MS.  It has served as the main avenue for determining the current 
dogma of the phathophysiological basis of MS as an autoimmune inflammatory 
disease instigated by myelin reactive Th1 T-cells. A group in the 1920’s observed 
significant CNS inflammation after inoculating rabbits with a human spinal cord 
preparation, and thus originated EAE (Gold et al., 2006). The first description of 
EAE came almost 10 years later in monkeys that had been repeatedly injected 
with rabbit brain extracts in an attempt to reproduce encephalitic complications of 
the anti-rabies vaccine (Rivers, 1993).  In the years since, EAE has been 
reproducibly elicited in a variety of species ranging from rats to sheep to 
marmosets (Gold, et al., 2006). EAE exhibits many of the clinical, 
neuropathological and immunological aspects of multiple sclerosis  (Wekerle, 
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2008). For example, EAE is characterized histopathologically by focal areas of 
inflammation/demyelination and clinically by ascending paralysis involving the tail 
and limbs. A variety of methods exist for induction of EAE. Inoculation with crude 
CNS tissue homogenates or with one of several different components of myelin 
(myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte 
glycoprotein (MOG)) is able to produce an immune response resulting in the 
prototypical symptoms of EAE (Steinman & Zamvil, 2005). MOG is considered a 
unique autoantigen because of its ability to induce a demyelinating autoantibody 
response in addition to the classic encephalitogenic T-cell response (Gold, et al., 
2006). In addition to choice of inoculum, to enhance the immune response and 
hasten induction, researchers use oil-based Freund’s adjuvant supplemented 
with heat-inactivated mycobacteria tuberculosis (complete Freund’s adjuvant, 
CFA). The defined disease activity varies with method of inoculation and species 
type. Induction using PLP in PL/J mice results in relapsing EAE, while MOG 
induces a chronic progressive course C57/BL6 mice and CNS tissue 
homogenate or MOG induces relapsing-remitting disease in Biozzi ABH mice 
(Gold, et al., 2006).  
 
Though EAE has parallels with MS, there are multiple differences between the 
two, and consequently, several pitfalls to this animal model. For instance, MS is a 
spontaneous disease, while EAE is actively induced by sensitization with brain 
tissue antigens. It is possible that this artificial induction of a myelin-specific 
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immune response may circumvent integral pathologic processes at work in 
human disease (Friese et al., 2006). Furthermore, most protocols for EAE 
induction use strong immune adjuvants (mentioned above) to boost the immune 
system, and it is very questionable whether a similar immune boost could occur 
under natural conditions in humans, even in the case of infection (Friese et al., 
2006). Also, EAE is studied in genetically homogenous populations, so the 
genetic heterogeneity that contributes to variability of presentation, course, and 
pathology in humans cannot be imitated. Perhaps, most importantly, some 
treatments showing efficacy in EAE have failed or worsened symptoms in MS 
(Steinman & Zamvil, 2005). Even with its faults, EAE is still the main and most 
well characterized animal model of MS and as such is valuable in deciphering the 
principal factors that contribute to the pathogenesis of the disease – including a 
role for the Fas system. 
 
Before discussing in detail the findings Fas studies in EAE, it is worth mentioning 
current studies in MS patients. Human data on the significance of Fas is scarce, 
but the few studies that do exist suggest there are perturbations of this receptor 
that result in resistance to apoptosis and therefore prolonged life in 
encephalitogenic T-cells. One study of peripheral blood mononuclear cells 
(PBMCs) from MS patients found decreased Fas expression specifically in CD4+ 
T-cells expressing CCR5. CCR5 is a chemokine receptor highly expressed in 
perivascular CNS infiltrating T-cells and implicated in MS (Julià et al., 2006). A 
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separate study examining the gene expression profile of PBMCs found that the 
negative regulator of Fas-induced apoptosis (TOSO) was upregulated in cells 
collected from MS patents compared to age- and sex-matched controls (Achiron 
et al., 2007). These studies suggest dysregulation and decreased expression of 
Fas in the lymphocytes of MS patients plays a role in protecting pathogenic T-
cells and, consequently, contributes to the disease process. 
  
Investigations into the effects of FasL administration or neutralization on EAE 
outcomes have been contradictory. Intrathecally administered recombinant FasL 
(before disease onset) appears to result in a dose-dependent suppression of 
EAE along with lessened pathological inflammation upon histological analysis 
(Zhu et al., 2002). Zhu et al. suggested this protective effect stemmed from 
infused FasL preventing initial infiltration of T-cells and macrophages into the 
CNS. Contrary to these results, intracerebroventricularly administered FasL did 
not affect EAE clinical scores, and subcutaneous administration of FasL 
significantly worsened EAE (Ciusani et al., 2001). Differences in outcomes could 
be attributed to site/mode of administration, sex differences, and method of EAE 
induction. Therefore, net beneficial effects, or appropriate route of FasL 
administration for alleviating EAE remains to be ascertained. In an alternative 
approach, Wildbaum et al. performed a neutralizing study using autoantibodies 
against endogenous FasL. Injection of anti-FasL antibodies resulted in significant 
protection when administered at the onset of EAE, but actually prevented 
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spontaneous recovery when administered after the peak of the acute phase of 
the disease (Wildbaum et al., 2000). These results suggest Fas plays 
complicated, stage-dependent roles in EAE – where Fas may initially contribute 
to CNS damage, but an active Fas system must be present for the clearing 
inflammatory T-cells and consequent remission. 
 
The role of the Fas system in EAE has been investigated in mice carrying 
autosomal recessive mutations for Fas (lpr) and FasL (gld). Lpr mice have a 
retroviral insertion of poly(A) adenylation signal repeats in the gene for Fas 
(Nagata & Suda, 1995). This large insertion results in improper splicing and 
truncation of Fas mRNA so that the cells are devoid of protein expression. In gld 
mice, there is a point mutation in the gene encoding FasL which disables its 
ability to interact with and activate Fas (Nagata & Suda, 1995). The development 
of both lpr and gld mice is normal, but as the mice age they are prone to 
developing lymphoproliferative disease and/or a spontaneous autoimmune 
syndrome with similarities to systemic lupus eyrthematosus (Cohen & Eisenberg, 
1992). The data from EAE induction in these Fas or FasL deficient animals is as 
varied and conflicting as the studies mentioned above.  Comparison of wild-type 
mice to lpr and gld mice revealed these mutations resulted in relative resistance 
to developing EAE (Waldner et al., 1997). Similarly, Okuda et al. found the 
frequency of induced EAE in lpr mice was 19% compared to 94% in wild-type 
mice (Okuda et al., 1998). However, the role of Fas in development of EAE is not 
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so simple, as other reports show either no difference or significantly worsened 
EAE clinical symptomology (Dittel et al., 1999; Suvannavejh et al., 2000). In a 
study by Dittel et al. EAE induction in lpr, gld, and wild-type mice all resulted in 
similar disease scores, suggesting Fas/FasL has little importance in the 
generation of EAE (Dittel et al., 1999). Contrary to all these studies, Suvannavejh 
et al. found that EAE induction in lpr mice resulted in significantly worsened 
disease - as defined by mean peak clinical scores, reduced remission rates, and 
increased mortality compared to controls (Suvannavejh et al., 2000). As before, 
these studies vary in their use of mouse strain and induction method for EAE. 
Overall, Fas/FasL most likely plays a significant role in pathogenesis and course 
of EAE, but before this importance can be established, more standardized 
approaches to investigating the lpr and gld models will need to be undertaken. 
Other options include using a more simplified, in vitro system where variables 
can be more tightly manipulated, or cell-specific ablation of Fas (both will be 
explored in this thesis). 
 
Summary 
Ultimately, elucidating the signals involved in the cross-talk that occurs within MS 
lesions should eventually allow us to manipulate various aspects in order to tip 
the balance in favor of brain repair. Although NPC have shown clinical efficacy in 
animal models and the immunoregulatory functions of NPC have been 
established, the critical mediators responsible for this bystander effect are not 
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well understood. Furthermore, the specific effects of T-cells on NPCs remain 
unexplored. Finally, NPC survival and differentation post-transplantation are 
important challenges that need to be addressed before NPC transplantation 
therapy becomes a viable therapeutic option.  
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Abstract 
 
Though there is a sizable amount of research focusing on adult neural progenitor 
cells (NPC) as a therapeutic approach for many neurodegenerative diseases 
including multiple sclerosis, little is known about the pathways that govern NPC 
survival and apoptosis. Fas, a member of the death receptor superfamily, plays a 
well characterized role in the immune system but its function in neural stem cells 
remains uncertain. Our study focuses on the effects of Fas on NPC survival in 
vitro. Activation of Fas by recombinant Fas ligand (FasL) did not induce 
apoptosis in murine NPCs in culture. In fact, both an increase in the amount of 
viable cells and a decrease in apoptotic and dying cells were observed with FasL 
treatment. Our data indicates FasL-mediated adult NPC neuroprotection is 
characterized by a reduction in apoptosis, but not increased proliferation. Further 
investigation of this effect revealed that the anti-apoptotic effects of FasL are 
mediated by the upregulation of Birc3, an inhibitor of apoptosis protein (IAP). 
Conversely, the observed effect is not the result of altered caspase activation or 
FLIP (Fas-associated death domain-like interleukin-1beta-converting enzyme 
inhibitory protein) upregulation, which is known to inhibit caspase-8 mediated cell 
death in T-cells.  
 
Our data indicates murine adult NPCs are resistant to FasL induced cell death. 
Activation of Fas increased cell survival by decreasing apoptosis through Birc3 
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upregulation, a member of the IAP family of proteins. These results describe a 
novel pathway involved in NPC survival.  
Introduction  
Neural progenitor cell apoptosis is significant in a variety of central nervous 
system (CNS) diseases ranging from Alzheimer’s disease to Multiple Sclerosis 
(Camins et al. 2008; Haughey et al. 2002; Sohur et al. 2006). Fas (a member of 
the TNF death receptor superfamily) is known to contribute to the maintenance of 
lymphocyte homeostasis and the deletion of autoreactive T-cells (Nagata & 
Golstein, 1995). The clinical effects of stem cell therapy in experimental 
autoimmune encephalomyelitis (EAE - the animal model of MS) are mediated by 
the induction of pro-inflammatory Th1 apoptosis via the Fas pathway by NPCs 
(Pluchino et al., 2005). However, the role of Fas/FasL in adult NPC physiology 
remains unknown.  
 
Fas is believed to play a critical role in regulating programmed cell death during 
embryonic development of the nervous system because of its expression during 
critical periods of neuronal apoptosis and differentiation (Cheema et al., 1999; 
Park et al., 1998; Raoul et al., 1999). Fas is involved in developmental neuronal 
death in both motor neurons (Nat et al., 2001)  and cortical neurons (van 
Landeghem et al., 2002). Recent studies have also implicated Fas involvement in 
cell processes other than cell death. A study investigating apoptosis in adult 
neural stem cells and a neural stem cell line (C17.2) found that the mitochondrial 
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pathway was active, but Fas-dependent cell death was not operational 
(Ceccatelli et al., 2004). Desbarats and colleagues have demonstrated that Fas 
can mediate proliferation and regeneration via the ERK pathway in neurons 
(Desbarats et al., 2003). Further characterizing the role of this system in neuronal 
development, Fas appears to regulate neuronal branching in hippocampal 
neurons (Zuliani et al., 2006). Additionally, human brain endothelial cells are 
resistant to FasL-mediated death, and triggering Fas induces release of matrix 
metalloproteinase 9 (Wosik et al., 2007). Thus it appears that the consequence 
of Fas activation is varied and cell type specific. Although Fas is a ubiquitous 
receptor found on cells throughout the body, its specific role in various cell types 
is not known.  
 
We investigated the effects on murine NPC survival, proliferation, and 
differentiation in vitro during Fas activation by its cognant ligand (FasL). Our 
results indicate that cells grown in minimal medium cell culture (deprived of 
growth factors) have an increased cell survival following Fas activation. This 
apparent neuroprotection arises from decreased apoptosis as opposed to 
augmented cellular proliferation. Furthermore, we found this effect is not as a 
result of altered FLIP expression or alterations of the caspase pathway. Rather, 
our data show the upregulation of mRNA levels and protein expression of Birc3, 
a largely undescribed member of the IAP family of proteins, thus providing a 
molecular mechanism for the protective effect of FasL. 
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Methods 
Isolation of Murine NPCs 
Mouse NPCs were obtained from Dr. Jeffrey Spees, University of Vermont Stem 
Cell Core.  NPCs were isolated from whole brains of individual 4-day post-natal 
C57/BL6 mice using NeuroCult® Enzymatic Dissociation Kit (Stem Cell 
Technologies). NPCs were identified based on neurosphere formation then 
enzymatically dissociated before culturing in a single-cell monolayer.   
 
In the same manner, NPCs were isolated from lpr (Fas-deficient) mouse pups for 
specificity experiments. Lpr mice have a retroviral insertion of poly(A) adenylation 
signal repeats in the gene for Fas (Nagata & Golstein, 1995). This large insertion 
results in improper splicing and truncation of Fas mRNA so that the cells are 
devoid of protein expression. 
 
Cell Culture 
The undifferentiated murine neural progenitor cells and neurospheres were 
cultured in Nunclon delta-coated 75cm2 filter flasks (Nunc) in mouse NPC 
complete medium: [1x Neurobasal-A (Invitrogen), 1x B27 supplement 
(Invitrogen), 20 ng/ml EGF (BDbiosciences), 10 ng/ml basic FGF (Peprotech), 2 
mM L-glutamine (Mediatech Inc.), 100 units/ml penicillin, and 100 µg/ml 
streptomycin (Mediatech Inc.)].   
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Statistical Analysis 
One way ANOVA was performed to determine statistical significance of the data, 
followed by Tukey’s test to compare individual samples. Analyses were run using 
Prism 5 (Graph Pad) software. 
FasL Treatment 
To assess the effect of FasL on NPCs, the cells within four to five passages were 
cultured in poly-D-lysine and laminin coated plates. Upon reaching 80-90% 
confluency (approximately 3 days), EGF and bFGF were withdrawn, cells were 
rinsed, and the cells were treated with recombinant FasL (Alexis Biochemicals) 
along with an enhancer (anti-flag M2 monoclonal antibody – Sigma) in minimal 
media [1x Neurobasal-A (Invitrogen), 1x B27 supplement (Invitrogen), 2 mM L-
glutamine (Mediatech Inc.), 100  units/ml penicillin, and 100 µg/ml streptomycin 
(Mediatech Inc.)]. Concentration of FasL was 200 ng/mL for all experiments, 
except for the 700 ng/mL Calcein AM experiments. Similarly, an enhancer (anti-
Flag, Invitrogen) used at the concentration of 4 µg/mL except for the higher 
concentration Calcien AM experiment, where 14 µg/mL was used. Some 
treatments were done in complete medium (as described in results). 
Flow Cytometry 
NPCs left in suspension of complete medium  in a 5 mL Falcon® tube (12X75 
mm) for 2-3 hours before pelleting, rinsing, and FasL addition. FasL treatment 
was performed in the presence, or absence of growth factors (i.e. in complete 
media or minimal media, respectively). Flow cytometric evaluation of apoptotic 
and dead cells was performed with Annexin V Alexa Flour 647 Conjugate assay 
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and LIVE/DEAD® blue-fluorescent (UV) reactive dye kit, respectively (both 
Invitrogen), according to manufacturer instructions. UV LIVE/DEAD dye 
permeates into and reacts throughout the volume of cells which have lost their 
membrane integrity, thus labeling necrotic cells. Annexin labels phospholipid 
phosphatidylserine residues on the exterior surface of apoptotic cells 
(translocation of PS is one of the earliest indicators of apoptosis).  Flow 
cytometry analysis was performed by a BD LSRII  flow cytometer equipped with 
3 lasers (488, helium neon, and UV) and data were analyzed with Flow Jo 
software. 
Cell Viability Assay 
Calcein AM (acetomethoxy derivate of calcein) assay is a commonly used 
method to meausure cell viability. Calcein AM enters living cells and is 
hydrolyzed by intracellular esterases to produce calcein, a strongly fluorescent 
compound that remains in the cytoplasm. Calcein AM was added directly to cells 
24 and 48 hours post treatment. Murine NPCs were cultured in 48-well plates 
and FasL treatments perfomed in minimal media were compared to untreated, 
minimal media controls. Both FasL and minimal media control NPCs were 
treated with 2 μg/mL Calcein AM (1 mg/mL stock diluted 1:500) and incubated at 
37C, 5% CO2, for approximately 30 minutes. Viability measurements were 
completed using Fluostar Galaxy spectrophotometry software. The data are 
described as relative absorbance (n=8 per condition).  
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Mouse NPC BrdU Proliferation Assay  
Cell proliferation in the presence of FasL was characterized by 
bromodeoxyuridine assay. Upon reaching approximately 80% confluency 
mNPCs were pulsed for 90 minutes with 100 M bromodeoxyuridine (a thymidine 
analog used during DNA synthesis) and fixed with 4% paraformaldehyde and 
picric acid (Zamboni’s). DNA was denatured using 2 M HCl and blocked (10% 
Horse serum, 0.2% Azide). The primary antibody mouse anti-BrdU IgG (Roche) 
was applied (1:100) and allowed to react overnight. A Cy3 anti-mouse secondary 
antibody (1:500) was applied and reacted for three hours. Cell counts were 
conducted by selecting random fields at a power of 20X and counted by hand. 
Total cell count was compared against BrdU positive cell nuclei to characterize 
mNPC proliferation. Percentage of positive cells was extrapolated using 
Neurolucida Stereoinvestigator Software (n=6 per condition). 
 
TUNEL Assay  
Terminal transferase dUTP nick end labeling (TUNEL) assay was performed to 
assess cell death from apoptotic signal cascades. Biotinylated dUTP (Roche) 
was incorporated into late stage apoptotic DNA using terminal deoxynucleotidyl 
transferase (Promega). Cells were stained with streptavidin fluorescein 
isothiocyanate (1:1000; Jackson Immunoresearch), a biotin ligand. Cell nuclei 
were labeled with Hoechst dye (1:2000) and visualized with UV microscopy. Cell 
counts were conducted by selecting random fields at a magnification of 20X and 
counted by hand comparing total Hoechst signal (491 nm) versus apoptotic 
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nuclei positive for Strep-FITC (515-565 nm). The percentage of positive cells was 
extrapolated using Neurolucida Stereoinvestigator Software (n=4 per condition). 
 
RT-qPCR  
Total RNA was isolated from both triplicate FasL-treated and minimal media 
controls using RNeasy Mini Kit (Qiagen). cDNA was amplified using Superscript 
IIITM First-Strand Synthesis Supermix for qRT-PCR (Invitrogen). NPC RNA was 
quantified by Nanodrop and synthesis of cDNA was completed using 
Superscript III First-Strand Synthesis Supermix (Invitrogen). mNPC cell fate and 
FasL expression analysis was completed using Applied Biosystems 7500 Fast 
Software real time-quantitative polymerase chain reaction (RT-qPCR). 
Amplification consisted of 50 cycles (95C for 15 seconds and 60C for 1 minute) 
with approximately 15 ng/L cDNA, specific primer pairs for β-tubulin III, 
PDGFRα, GFAP, and GLAST; and TaqMan Master Mix (all Applied Biosystems).  
Neuron (β-tubulin III), astrocyte (GFAP and GLAST), and oligodendrocyte 
(PDGFRα) mRNA transcript expressions were analyzed. Cycle threshold 
amplifications for mNPC cDNA were normalized against endogenous control 
marker Actin and subsequently expressed as fold differences relative to lineage 
marker and treatment condition. The 2-∆∆Ct method was used to calculate the 
relative expression of genes. Same methods were used with Birc3/c-IAP2 primer 
(also from Applied Biosystems, Assay on Demand). For each primer, the 
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experiment was replicated 3 times (n=3). RT-qPCR experiments were replicated 
6 times (n=6) 
Immunocytochemistry 
Cells were plated on coated (poly-D and laminin) coverslips in 12-well plates. 
After the treatment period, cells/coverlips were fixed Zamboni’s Fixative (4% 
paraformaldehyde; 15% picric acid). Cells were incubated overnight at 4οC in the 
following anti-mouse antibodies: nestin (Novus Biologicals, 1:250), β-tubulin III 
(AbCam, 1:100) GFAP (Eucor Biotech, 1:500), and NG2 (R&D, 1:500). The 
nestin antisera was made in chicken, all the rest were made in rabbit. After 
rinsing twice in phosphate buffered saline, cells were incubated for 2 hours at 
room temperature in both anti-chicken Cy2 (1:250) and anti-rabbit Cy3 (1:500) 
secondary antibodies (both Jackson Immunoresearch) 
Western Blot Analyses   
For Western blot analyses, the mNPC cultures were lysed in 2X lysis buffer with 
0.5% NP-40 (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2mM sodium 
orthovanidate, 10% glycerol, and 1 tablet/25mL “Complete” protease inhibitor 
[Roche Diagnostics]) SDS). The proteins (32 μg) were fractionated on 4 - 12% 
SDS-PAGE gels and transferred onto Immobilon-P PVDF membranes (Millipore) 
for Western analyses using primary antibodies to FLIP (ProSci Incorporated), 
caspase-8 (Apotech), caspase-3 (not commercially avalible, gift from Dr. Ralph 
Budd), β-tubulin III (Sigma), GFAP (Applied Biological Material), myelin 
oligodendrocyte glycoprotein (MOG, R & D Systems), and actin (Santa Cruz); the 
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blots were stripped in 62.5 mM Tris-HCl, pH 6.7, containing 2% SDS and 100 
mM β-mercaptoethanol at 50 oC for 90 min before each reprobing procedure. 
Horseradish peroxidase-conjugated secondary antibodies were used. The blots 
were processed for enhanced electrochemiluminescence detection (GE 
Healthcare); all blots were exposed to autoradiographic film for signal detection. 
Two separate Western blot experiments were performed for the FLIP/caspase-
8/caspase-3 probing. Blots using c-IAP2/Birc3 (Santa Cruz) as a primary 
antibody were processed similarly except secondary antibody (goat anti-rabbit 
alexa fluor 680-conjugated: Molecular probes) was incubated in Odyssey Buffer 
and signal detection was performed using Odyssey 2.0 infrared imaging system. 
Birc3 western blot experiment was replicated three times (n=3).  
 
Results 
 
Murine NPCs express Fas and FasL 
To confirm the presence of Fas on murine NPCs, both surface receptor and 
mRNA expression were investigated. Surface receptor expression was confirmed 
using flow cytometry. Mouse CD4+ cells were used as a positive control because 
T-cells are known to be high expressors of Fas. mNPCs and T-cells were stained 
with a Fas-specific antibody conjugated to PE. Intensity of fluorescence revealed 
mNPCs are positive for Fas, and levels are comparable to that which is seen in 
T-cells (see Figure 1). 
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Expression of FasL in mNPC minimal and complete media cultures and 
unstimulated mouse CD4+ T-cells was determined using RT-qPCR. Ct values 
(from both mouse apoptosis Superarray plate analysis and RT-qPCR) indicated 
low levels of FasL mRNA expression in NPCs grown in minimal and complete 
media (average Ct values of 38.2 and 36.8, respectively). These expression 
levels are very low compared to average T-cell expression levels (average Ct 
value = 27.7). These data indicate that adult NPCs express high levels of the Fas 
receptor, but minimal amounts of FasL in primary culture. 
 
FasL induces cell death in T-cells but not NPCs 
To elucidate the physiological role of Fas/FasL in adult NPCs, we tested the 
ability of recombinant FasL to induce cell death. Induction of apoptosis and 
quantity of dead cells was assessed at two time points (3 hrs and 15 hrs) using 
UV Live/Dead Dye and Annexin staining. UV Live/Dead dye permeates into and 
reacts throughout the volume of cells which have lost their membrane integrity, 
thus labeling necrotic cells. Annexin labels phospholipid phosphatidylserine 
residues on the exterior surface of apoptotic cells (translocation of PS is one of 
the earliest indicators of apoptosis). Mouse T-cells (isolated from lymph nodes of 
wild-type C57/BL6 mice) were used as a positive control because they are known 
to be sensitive to FasL induced cell death.  At both 3 hr and 15 hr time points, a 
substantial amount of FasL induced cell death was observed in the T-cells when 
compared to untreated controls. There was a 4-fold increase in the percentage of 
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dead and dying T-cells at 3 hrs with FasL treatment, while FasL treatment 
increased the percentage of dead and dying T-cells from 34.2% to 85.8% at the 
15 hr time point (Figure 2a, top row). Similar results were obtained when using 
human Jurkat T-cells (data not shown). 
 
We did not observe any FasL-induced cell death in the NPCs at the early or late 
time point in either complete or minimal media (middle and last rows of Figure 
2a). Interestingly, for cells incubated in minimal media, we observed a decreased 
percentage of dead and dying cells in the FasL treated NPC at 15hrs (Figure 2b, 
bottom panels). 80% of control NPCs stained positive for UV Live/Dead and/or 
Annexin dyes while only 62% of FasL-treated cells were positive. Therefore, it 
appeared FasL may exhibit a protective effect against apoptosis.  
 
FasL increases NPC survival upon growth factor withdrawal 
When NPCs are deprived of epidermal growth factor and fibroblast growth factor 
(i.e. when cells are placed in minimal medium), a large number of cells die (Kuhn 
et al., 1997; Slinskey et al., 1999). In order to determine if FasL exposure 
increased cell survival under growth factor deprivation conditions, we assessed 
cell viability using Calcein AM assay. FasL treated NPCs were compared to 
control NPCs at 24 and 48 hours. No change was observed in treated (at either 
200 ng/mL or 700 ng/mL concentrations) versus control at 24hrs (Figure 3a). 
However, at 48 hours (see Figure 3b) there was a dose-dependent response, 
64 
  
with FasL-treated cells having increased survival. These results are consistent 
with the flow cytometry data discussed above. Therefore two different methods of 
assessing cell viability demonstrate more NPCs survive under conditions of 
growth factor starvation when Fas is activated. 
 
Decreased murine NPC apoptosis with FasL treatment  
The results from annexin/UV live-dead dye and Calcein AM assays prompted us 
to investigate whether the protective effects of FasL in NPCs were due to a 
decrease in apoptosis, an increase in proliferation, or both. Results from the 
TUNEL assay showed a trend in the direction of decreased apoptosis for FasL 
treated cells at 24hrs (see Figure 3c), although this did not differ significantly 
from untreated controls. However, FasL-treated cells had a significantly lower 
percentage of apoptotic cells (see Figure 3d) after 48 hours lacking growth 
factors.  
 
FasL does not influence NPC proliferation or differentiation 
To assess whether FasL possesses proliferative properties in NPC, a series of 
BrdU-labeling studies was performed. In EGF- and FGF-supplemented medium, 
more than 75% of NPCs were labeled with BrdU, demonstrating the high 
proliferative state of the cells under optimal culture conditions. Growth factor 
withdrawal diminished NPC proliferation precipitously to less than 7% of the 
population. FasL-treated cells showed a similar percentage of BrdU+ cells 
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(Figure 4a). Therefore, these data show that the increase in viability of NPCs 
following Fas activation is the result of decreased apoptosis. 
 
In addition to attenuating apoptosis in NPCs, Fas could play a role in 
differentiation. Effects of FasL exposure on mNPC differentiation were assessed 
using both RT-qPCR and immunocytochemistry. RT-qPCR revealed that the 
mRNA expression levels of GFAP and GLAST (astrocyte markers), β-tubulin III 
(neuron marker), and PDGFR-α (oligodendrocyte marker) were not significantly 
different when comparing FasL treated NPCs to control NPCs in minimal media 
(Figure 4b). Control cells were used as the calibrator sample and normalized to 
β-actin. Thus, Fas activation does not facilitate differentiation into astrocytes, 
neurons, or oligodendrocytes. The RT-qPCR data are consistent with 
immunocytochemistry results (Figure 4c).  
 
FasL treatment does not affect the levels of FLIP, caspase-8, or caspase-3 in 
NPCs 
In light of our data supporting decreased apoptosis after Fas activation, we 
sought to investigate the intracellular pathways that may be responsible for this 
effect. Fas mediates cell death by way of the extrinsic pathway, whereas 
activation of the receptor causes receptors to oligomerize - subsequently 
inducing the formation of DISC (death-inducing signaling complex), which 
includes FADD (Fas associated death domain) and caspase-8 (Wajant, 2002). 
Proteolytic activity of the DISC complex results in the activation of caspase-8, 
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which consequently activates (either directly or indirectly, depending on the type 
of cell) caspase-3, the effector caspase (Wajant, 2002). FLIP, an inhibitor of Fas 
mediated cell death, acts by inhibiting the activation of caspase-8 (Nagata & 
Golstein, 1995). It is known that high levels of FLIP expression correlate with 
resistance to Fas-mediated cell death, while decreased expression of FLIP 
renders cells sensitive to apoptosis (Tschopp et al., 1998). Thus, we investigated 
whether altered FLIP expression could account for the anti-apoptotic effects of 
Fas activation we observed. Western blot revealed an increase in the p43 DISC-
associated cleavage form [FLIP(p43)], with a consequent decrease in the full 
length form in T-cell controls treated with FasL (Figure 5b) This pattern was not 
seen in treated NPCs, however, and there was no change in the FLIP expression 
pattern upon Fas activation. Thus, FLIP upregulation cannot explain the 
protective effects against apoptosis observed with Fas activation in NPC. 
 
Furthermore, we were interested in caspase-8 and caspase-3 protein expression, 
which are indicators of up- and down-stream stages of caspase mediated 
apoptosis, respectively. Levels of both caspase-3 and caspase-8 remain steady 
in T-cells (Figure 5c & 5d). This is likely due to active FLIP inhibiting the 
activation of caspase-8 (Tschopp et al. 1998). There was no difference in the 
expression of caspase-8 in FasL treated NPCs versus controls (Figure 5c). 
Furthermore, we found no change in pro-caspase-3 levels and no detectable 
induction of cleavage into the active form (see Figure 5a). Consequently, our 
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findings showed that the protective effects against apoptosis resulting from Fas 
activation are not the result of FLIP upregulation, nor the inhibition of caspase-8 
or caspase-3 activity in the extrinsic cell death pathway. Additionally, our 
Western results on the levels of these caspases were consistent with our initial 
experiments that show no induction of cell death. 
 
The anti-apoptotic gene Birc3 is responsible for FasL anti-apoptotic effects 
The novel finding of increased cell survival, without involvement of FLIP, led us to 
search for possible genes that could be involved in this process. We used a 
mouse apoptosis PCR micro-array to (SuperArray) screen for genes involved in 
FasL anti-apoptotic effects on NPC. We found that the IAP Birc3 (also known as 
cIAP-2) was upregulated by a factor of 7.19 (p<0.000001) in FasL treated cells 
compared with controls (averaged from 3 samples each of FasL-treated and non-
treated NPCs in minimal media). Birc3 mRNA upregulation appeared to be 
specific, as other anti-apoptotic genes were not affected by FasL treatment 
(Table 1). This finding was confirmed using Applied Biosystems assay on 
demand primer for Birc3/c-IAP2 (Ref Seq #: NM_007464.3; Assay ID: 
Mm00431800_m1). Results showed an increased Birc3 mRNA expression of 
approximately 7.63 fold (SD= +/-1.53, n=4) in FasL-treated cells compared with 
controls (Figure 6a). Western blot analysis was consistent with the mRNA data, 
showing a statistically significant increase in Birc3 protein expression in the 
FasL-treated sample (Figure 6b). Birc3 is one of several genes in the IAP family 
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that were originally identified in baculoviruses where they inhibited infected cells 
from death (Schimmer, 2004).  
FasL effects on NPCs are specific 
It is possible that the observed effects on NPC could work through some Fas-
independent/non-specific mechanism. In order to explore this possibility, we 
compared the effects of FasL on wild type and Fas-deficient (lpr) NPCs. Both lpr 
and wild-type NPCs were treated with FasL or control (minimal media) for 48hrs, 
as in previous experiments. Afterwards, RNA was extracted and the expression 
level of Birc3 mRNA was analyzed using RT-qPCR. In contrast to wild-type 
NPCs, there was no difference in apoptosis for FasL and control lpr samples 
(Figure 7). This is indicative of a specific interaction between FasL and its 
cognant receptor that leads to a decrease in apoptosis. 
 
Discussion 
We investigated the effects of FasL/Fas on neural progenitor cell survival, 
proliferation, and differentiation in vitro. NPCs express high levels of FasR, and 
relatively low levels of FasL.  
 
Our data show that under optimal conditions (complete media with growth 
factors), Fas activation via FasL in NPCs does not induce apoptosis. This is in 
contrast to T-cell controls (known to be highly sensitive to Fas-induced cell 
death), which demonstrated a significant amount of cell death following Fas 
69 
  
activation. In the absence of growth factors (under minimal medium conditions), 
FasL promoted NPC survival and abrogated the apoptosis response. Our 
findings are in line with results of other studies with adult NPCs (Ceccatelli et al., 
2004), neuronally differentiatied precursor cells (Brunlid et al., 2007), and a 
neural stem cell line (Tamm et al., 2004), all of which also find no induction of 
apoptosis after Fas activation using various methodologies. Although insensitivity 
to Fas-induced cell death in NPCs has been previously reported (Brunlid et al., 
2007; Ceccatelli et al., 2004), ours is the first and only study that suggests a 
protective effect of Fas activation against apoptosis. 
 
To our knowledge, this is the first study that begins to provide a detailed 
characterization of the intracellular pathways involved in Fas activation. Our 
results show that FLIP, an inhibitor of caspase-8 mediated cell death, is not 
involved in the inhibition of apoptosis. In addition, we found no activation of 
caspase-8 or caspase-3, further supporting findings of the lack of apoptosis 
induction with Fas activation in NPCs. It is possible that caspase-8 levels in NPC 
are not sufficient to initiate the apoptosis cascade (Ricci-Vitiani et al., 2004). 
Interested to find what other genes could be involved in this process, we 
discovered Birc3, an IAP, is up-regulated following Fas activation providing a 
probable mechanism for the anti-apoptotic effects of FasL on NPCs. 
Furthermore, presence of Fas is required for observed anti-apototic effects to 
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occur. Therefore, FasL does not work through a non-specific mechanism or 
alternate pathway. 
 
The identification of factors capable of maintaining CNS NPC populations is 
important in a variety of contexts.  Developmentally, the rates of NPC apoptosis 
and differentiation are determinants that define neuronal populations and 
cytoarchitecture.  In adults, continuous NPC renewal has been implicated in 
learning and memory, maintaining olfactory function, mediating therapeutics for 
behavioral or psychiatric disorders, and providing an endogenous means of 
neuronal repair after injury (Gould et al., 1999; Okano et al., 2007; Sahay & Hen, 
2007; Sohur et al., 2006). If accumulating cellular insults, or changes in 
environmental niches result in decreased NPC regenerative capacity to repair 
CNS damage from degenerative diseases or injury, then diminished NPC 
apoptosis may be an important contributor to the constellation of neurological 
defects associated with CNS repair.  Several growth factors and cytokines, 
including EGF, bFGF, vascular endothelial growth factor (VEGF), brain derived 
nerve growth factor (BDNF), prolactin, leukemia inhibitory factor (LIF) and ciliary 
neurotrophic factor (CNTF) have been shown to be capable of promoting stem 
cell renewal; the addition of FasL to the repertoire not only presents alternatives, 
but also options for coordinate treatments to amplify and refine NPC survival. 
Although the role of Fas for immunoregulatory cells is fairly well characterized, 
the role of Fas in neural stem cell physiology is not clear.  
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Our results suggest a novel role for a member of the IAP family, Birc3, in 
promoting neural stem cell survival following activation of the Fas/FasL pathway. 
IAPs are a family of anti-apoptotic proteins that specifically inhibit caspase-3, -8, 
and 9 (Schimmer, 2004). A total of 8 proteins have been identified in humans 
thus far, based on both presence of BIR (baculovirus IAP repeat) domain and 
anti-apoptotic activity (Schimmer, 2004). Little is known about the functions of 
IAPs, particularly c-IAP2/Birc3, in the nervous system. Different members of the 
IAP family have been investigated for involvement in various neurological 
diseases. For example, neuronal apoptosis inhibitor protein (NAIP) is 
upregulated in rat neurons in response to transient forebrain ischemia (Xu et al., 
1997). At molecular level, IAP-1 and -3 are down-regulated in microglia following 
treatment with transforming growth factor (TGF)-β, thus indicating a role for IAPs 
in mediating CNS inflammatory response (Jung et al., 2003). Knowledge of these 
mechanisms could be translated to therapeutic technologies for diseases like 
MS. Furthermore, increased IAP expression in the T-cells of MS patients 
correlates with disease activity, while interferon-beta therapy decreases IAP 
expression in these cells (Semra et al., 2002; Sharief et al., 2002). This 
implicates IAP expression as an important regulator of T-cell survival in, and thus 
pathology of MS. The full involvement of IAPs and the specific pathways they 
affect remain to be elucidated in both healthy neuronal cells and in disease 
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states. Further elucidation of this and other pathways regulating the apoptosis of 
NPCs are required before their full therapeutic potential can be obtained. 
 
It is possible that the role of Fas changes depending on the developmental stage 
and proliferative properties of the stem cells.  Different from our observations, 
Fas monoclonal antibody Jo2-induced apoptosis of wild type embryonic stem 
cells (ESCs) isolated from 15 day-old mouse but not the ESCs from Fas-/-(lpr) 
mice (Semont et al., 2004). A recent study on human ESCs found Fas, FasL, 
caspase-8, and caspase-3 are all up-regulated after exposure to the toxic 
environmental contaminants nonylphenol and octylphenol (Kim et al., 2006). It is 
unclear whether the Fas up-regulation in response to toxins in this study had a 
net protective or death-inducing effect. These results appear contrary to our work 
and other work with adult NPCs (Ceccatelli et al., 2004), neuronally differentiated 
progenitor cells (Brunlid et al., 2007) and a neural stem cell line (Tamm et al., 
2004), all of which demonstrate that Fas-dependent apoptosis pathway is not 
functional in these cells. Although the reasons of these differences are unclear, 
they may be related to the original source of the neural stem cells, culture 
maintenance and treatment conditions. Taken together, our findings and others 
suggest an important role of Fas in regulating developmental neuronal death. 
Fas may play an evolving, pluripotency dependent role in maintenance of the 
CNS. 
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Neural stem cell transplantation therapies are a promising investigative avenue 
for several neurodegenerative diseases. According to Pluchino’s findings, NPC 
transplantation results in a therapeutic effect for EAE mice, the widely used 
animal model of human CNS demyelinating diseases (Pluchino & Martino, 2005). 
It is thought that this observed effect could be mediated by a “bystander” process 
in which transplanted neural stem cells are able to inhibit destructive T-cells and 
promote the growth and survival of existing neurons by releasing neuroprotective 
molecules (Martino & Pluchino, 2006; Pluchino & Martino, 2008). This is in 
contrast to the “cell replacement” hypothesis, where transplanted neural 
progenitor cells repopulate a damaged CNS. In order to be able to harness the 
full therapeutic potential of neural stem cells, characterization of the biochemical 
mechanisms that regulate their survival is essential. Our study shows that the 
FasL/Fas pathway does not induce cell death in murine progenitor cells, and that 
FasL increases the survival of NPCs by decreasing apoptosis; Birc3 is a 
probable candidate for modulating this process, though further studies are 
required before a definitive statement can be made. Modulating this pathway 
may impact NPC survival and cell fate commitment, which may be important for 
NPC in vitro expansion and then in vivo therapeutic applications.  
 
Conclusion 
We investigated the effects of FasL/Fas on neural progenitor cell (NPC) survival, 
proliferation, and differentiation in vitro. We have found that FasL increases NPC 
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survival upon withdrawal from growth factors, without affecting cell differentiation 
properties. This increased cell viability appears to be the result of decreased 
apoptosis, rather than an increase in proliferation. The apparent protective effect 
against apoptosis induced by FasL is not a result of increased FLIP, a molecule 
known to inhibit caspase-8 mediated cell death in T-cells. However, a possible 
mechanism could be through Birc3, a member of the inhibitor of apoptosis family 
of proteins, that was found to be upregulated in cells treated with FasL. These 
effects were negated in Fas-deficient NPC, confirming the specificity of this 
interaction. Therefore, we describe a novel pathway for NPC survival involving 
the Fas system and Birc3. 
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Table 2-1: FasL effects on anti-apoptotic gene expression 
Table lists results from mouse apoptosis gene array analysis. RNA was extracted 
from NPC control and FasL (200 ng/mL) treated cells grown in minimal medium 
for 48 hrs. Of all the anti-apoptotic genes tested, the Birc3 was the only one that 
showed a significant change in mRNA expression with FasL treatement. Fold 
differences and p values obtained from averaging 3 separate arrays (n=3). 
Positive numbers indicate up-regulation while negative numbers indicate down-
regulation. Fold difference obtained by following equation: (2-ΔCt FasL)/(2-ΔCt 
Control).  
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Anti-Apoptosis 
Gene 
Fold Up- or Down-
Regulation                       
(FasL NPC/Control NPC) 
Akt1 1.07 
Api5 1.05 
Ataf5 -1.19 
Bag1 -1.15 
Bag3 -1.00 
Bcl2 1.27 
Bcl2l1 -1.15 
Bcl2l2 -1.08 
Birc1a 1.15 
Birc1b 1.07 
Birc2 1.07 
Birc3 7.19* 
Birc4 1.14 
Birc5 1.03 
Bnip3 1.05 
Casp2 1.25 
Cflar 1.49 
Dad1 2.06** 
Tsc22d3 1.01 
Hells 1.52 
ll10 1.69 
Lhx4 -1.29 
Mcl1 -1.02 
Nfkb1 1.02 
Nme5 1.09 
Pak7 1.21 
Pim2 1.19 
Polb 1.20 
Prdx2 -1.15 
Rnf7 -1.20 
Sphk2 1.01 
Tnf -1.03 
Cd40lg 1.08 
Zc3hc 1.12 
*p value <0.00001 
**p value > 0.05 
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Figure 2-1: NPCs express significant amounts of FasR 
PE conjugated monoclonal antibody to FasR detected using flow cytometry. 
Fluorescence represents % of maximum intensity, thus some cells have higher 
density of the receptor than others. Cells were stained with PE-conjugated FasR 
Ab for 30 min after blocking with isotype control antibody. PE fluorescence (blue 
line) is overlayed with baseline fluorescence (red) – obtained from cells were only 
blocked with isotype control  
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Figure 2-2: FasL does not induce cell death in NPCs 
 
T-cells and NPCs were treated with FasL (200 ng/mL) plus an enhancer             
(4 ug/mL) for 3 and 15 hrs at 37C before staining. All cells were stained with UV 
Blue Live/Dead dye and Annexin alexa-fluor 647. Cells were subsequently 
scanned using flow cytometry. For a-l, lower left quadrant (I) represents cells 
living healthy cells which stain negative for either dye; the lower right quadrant 
(II) represents early apoptotic cells which are positive for annexin; the upper right 
quadrant (III) represents dead and dying cells which stain positive for both 
annexin and UV Live dead dye; the upper left quadrant (IV) includes only necrotic 
cells (i.e. positive for only UV/Live dead dye). For T-cells growing in optimal 
culture conditions (complete RPMI supplemented with  IL-2), death was induced 
after 3 hrs of FasL treatment, as evidence by the approximate 4-fold increase in 
the percentage of apoptotic cells (i.e. annexin positive) in treated (b) versus 
untreated (a) samples. A dramatic increase in the amount of apoptotic and 
necrotic cells was observed in TCs treated with FasL for 15 hrs (d) compared to 
controls (c). No effect on NPCs was observed after 3 or 15 hrs of FasL treatment 
in complete neurobasal medium supplemented with EGF and FGF (e-h). No 
induction of death was observed in NPCs treated for 3 hrs with FasL in minimal 
medium (e) compared to control cells (f). A slight decrease (approximately 18%) 
in the total dead and dying cells was observed in NPCs treated with FasL for 15 
hrs (h) compared to controls (g). 
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Figure 2-3: Fas Activation promotes NPC survival by decreasing apoptosis 
Calciein AM (acetomethoxy derivate of calcein) assay is a commonly used 
method to meausure cell viability. Calcein AM enters living cells and is 
hydrolyzed by intracellular esterases to produce calcein, a strongly fluorescent 
compound that remains in the cytoplasm. In a-b fluorescence was measured 
using Fluostar Galaxy spectrophotometry software and the Y-axis (absorbance) 
is in arbitrary units and is equivalent to cell viability. (a) Calcien AM assay 
revealed no change in cell viability after 24 hrs in minimal media at two different 
concentrations of FasL. (b) At 48 hrs, there was a dose-dependent increase in 
cell viability for treated NPCs. The difference was statistically significant at 700 
ng/mL (p<0.05, n=8) using ANOVA. Y-axis (absorbance) is equivalent to cell 
viability.  (c) and (d) show results from TUNEL (terminal deoxynucleotidyl 
transferase Biotin-dUTP nick end labeling)  assay experiments, which allows for 
quantification of apoptotic cells by labeling  broken strands of DNA. Cells treated 
with FasL (200 ng/mL) in minimal medium are compared to control cells grown in 
minimal medium. Healthy NPCs grown complete medium (includes EGF and 
FGF growth factors) provide a negative control (leftmost column). (c) At 24 hrs 
following growth factor removal, there is a trend toward decreased percentage of 
apoptosis in NPCs treated with FasL. (d) A significantly decreased amount of 
apoptosis (p<0.01, n=4) was observed in NPCs treated with FasL treatment for 
48 hrs in the absence of growth factor. 
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Figure 2-4: Fas Activation does not influence NPC differentiation or 
proliferation 
(a) Cells treated with 200 ng/mL FasL were fixed and proliferation was 
subsequently assesed using BrDU-assay. No significant difference was detected 
between FasL treated cells and controls (minimal media). Results include 
proliferation of cells in complete media (with growth factors) for comparison. % of 
BrDU positive cells was determined by comparing with total number of cells 
(stained with Hoescht nuclear dye). Random fields were counted at 20X using 
Neurolucida Steroinvestigator Software. n=4 (# of slides per condition). (b) RNA 
extracted from NPC treated for 72 hrs with FasL in minimal media was subjected 
to cDNA reverse transcription, and the resulting cDNA was analyzed using RT-
qPCR. NPC cDNA were normalized against β-Actin (endogenous control marker) 
and subsequently expressed as fold differences relative to NPC grown in minimal 
media. Specific primer pairs for β-TubulinIII, platelet-derived growth factor 
receptor (PDGFR)-α, glial fibrillary acidic protein (GFAP), and astrocyte-specific 
glutamate transporter (GLAST) were utilized to determine mRNA expression. 
The 2-ΔΔCt method was used to calculate the relative expression of genes. FasL 
treatment had no effect on oligodendrocyte (PDGFRα), neuronal (beta-
TubulinIII), or astrocyte GLAST & GFAP) lineage differentation. Data represent 
the mean from 5 different cultures ±SEM (n=4, p>0.05). (c) Cells were grown to 
confluency on poly-D and laminin coated coverslips. Spontaneous differentiation, 
upon withdrawal of growth factors for 48 hrs (top panels) was compared to 48 hr 
FasL treated cells (bottom panels). Cells were fixed with Zamboni’s fixative and 
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then co-stained with anti-mouse nestin (chicken) and NG2, B-TubulinIII, or GFAP 
(all rabbit anti-mouse) primary antibodies. All coverslips were then stained with 
both anti-chicken Cy2 and anti-rabbit Cy3 secondary antibodies. Mounted slides 
were visualized using Nikon Eclipse E800 flourescent microscope and photos 
were taken using Photometrics CoolSNAPTM cf software. No significant 
difference in any lineage marker was observed upon FasL treatment (n=3). 
 
 
 
 
 
 
87 
  
 
 
 
88 
  
 
Figure 2-5: FasL does not influence FLIP or caspase levels in NPCs 
Western blot results for probing the signaling cascades involved in Fas 
activation. Cell lysates obtained using NP-40 after various treatment periods of 
200 ng/mL FasL + 4 ug/mL α-flag (enhancer). Blot was first probed using an anti-
FLIP antibody; then the blot was consecutively stripped and re-probed for 
caspase-8, caspase-3, and finally β-actin. Secondary antibodies were HRP-
conjugated, and visualized using ECL development reagents. FLIP levels remain 
unchanged in NPCs after FasL Treatment; NPCs express low levels of caspase-
8, and expression is not changed with FasL treatment at various time points; the 
levels of procaspase-3 (~29 kDa) remains unchanged; In contrast to T-cells the 
activated (cleaved) form of caspase-3 (~16 kDa) is not produced in NPCs after 
FasL treatment at various time points. 
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Figure 2-6: Birc3 upregulation correlates with Fas activation  
(a) RT-qPCR results showing mRNA expression of Birc3 is upregulated in FasL 
treated cells compared to controls after growing for 48 hrs in minimal medium. 
Control cells were used as calibrator sample and results normalized to β-actin 
mRNA expression. (b) Birc3 protein expression is significantly upregulated in 
NPCs treated with FasL. Cell lysates collected from control and FasL cells grown 
in minimal medium for 48 hrs. Top: Western blot probed with rabbit α-Birc3/cIAP-
2 antibody and then incubated with an α-rabbit secondary antibody conjugated to 
alexa Fluor 680. Positive band for Birc3 (~68 kDa) was visualized using 
Odyssey® infrared imaging system. Bottom: semi-quantitation of bands using 
densiometric analysis  (n=3, p<0.05 using Students t-test); protein levels were 
normalized to beta-actin. 
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Figure 2-7: Induction of Birc3 expression is dependent on Fas expression 
RT-qPCR results comparing Birc3 mRNA expression in FasL treated wild-type 
(wt) versus lpr (Fas-deficient) NPCs. Statistically significant Birc3 upregulation 
was observed in wt (p<0.01, n=3), but not lpr NPCs. Both wt and lpr NPCs were 
isolated from 4-day postnatal BL6/C57 mouse pups according to manufacturer 
instructions using NeuroCult® Kit for CNS tissues. Cells were grown into free 
floating neurospheres in complete medium before consequently dissociating into 
single cells an plating in a monolayer.  These monolayer cells were grown to 
80% confluency and treated with FasL for 48 hrs before RNA extraction. 
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Abstract 
Although transplanted neural stem/progenitor cells (NPCs) can ameliorate 
disease course in animal models of central nervous system inflammatory and 
neurodegenerative diseases, little is known about the regulation of NPC 
differentiation and proliferation. The Fas receptor, a member of the tumor 
necrosis factor (TNF) superfamily, has recently been shown to be important in 
NPC survival and immunoregulatory functions. We were interested in further 
investigating this system utilizing NPCs isolated from Fas-deficient (lpr) mutant 
mice.  
 
We found that lpr NPCs have increased survival and decreased proliferation. 
Additionally, RT-qPCR, confocal microscopy, and flow cytometry surface staining 
reveal that lpr NPCs have a significantly more robust differentiation to neuronal 
and oligoprogenitor cell lineages as compared to wild-type (wt) NPCs. These 
effects correlated with an upregulation of three of the major fate specification 
modulators in lpr NPCs: sonic hedgehog (Shh), slit homolog 2 (Slit2), and 
noggin.  
 
These data indicate Fas plays an important role in determining the stemness and 
differentiation fate of NPCs. Additionally, our research reveals a novel connection 
between Fas and major modulators of NPC differentiation – Shh, Noggin, and 
Slit2. This is the first indication of a possible link between Fas and these 
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particular signaling molecules that control neuronal fate specification. Therefore, 
our results suggest Fas is a novel target for controlling the development of 
neurons versus mature oligodendrocytes.  
 
Introduction 
There is a critical need for developing direct neuroregenerative therapies for 
demyelinating diseases, including Multiple Sclerosis (MS). Currently MS 
treatments are limited to peripheral immunoregulation and are ineffective in later, 
progressively neurodegenerative stages of the disease.  Neural stem/progenitor 
cell (NPC) therapies offer a potentially powerful treatment approach for the 
chronic neurodegeneration that occurs in these later stages (Pluchino & Martino, 
2005). The two main experimental modalities for NPC therapy are exogenous 
transplantation and activation/recruitment of the endogenous adult NPC 
compartment (Martino & Pluchino, 2006). In either method, differentiation and 
integration of NPCs to enhance central nervous system (CNS) repair is the most 
sought after outcome. Though exogenous application of NPC has shown 
significant recovery in animal models of MS (experimental autoimmune 
encephalomyelitis), the functional integration and terminal differentiation of 
transplanted cells is extremely rare (Pluchino & Martino, 2005; Pluchino et al., 
2005). The signaling pathways that control NPC survival and differentiation are 
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not well understood; therefore, elucidating these complex pathways is paramount 
for advancing this therapeutic approach.   
 
The Fas receptor (hereafter referred to as “Fas”) – a member of the TNF receptor 
superfamily - has emerged as a major modulator of NPC biology. Previous 
knowledge limited this receptor to cell-death related roles: in the immune system 
controlling homeostasis by inducing T-cell death (Nagata & Golstein, 1995), and 
in the CNS mediating programmed death during embryologic development (Nat, 
et al., 2001; van Landeghem, et al., 2002). However, Fas is now recognized as a 
mediator of diverse, cell-dependent mechanisms. Namely, activation of Fas via 
its cognant ligand (FasL) promotes survival in NPCs (Corsini et al., 2009; Knight 
et al., 2009). Furthermore, Fas activation induces neurogenesis and neurite 
outgrowth (Corsini et al., 2009).  These recent findings suggest that Fas plays a 
complex role in mediating NPC fate, and modulation of this pathway may be a 
crucial target for future therapies. 
 
In this study, we utilized NPCs isolated from the brains of Fas-deficient (lpr) 
mutant mice to further investigate the role of Fas in mediating NPC fate. Here we 
report that lpr NPCs exhibit increased survival, increased neuronal specification, 
and higher populations of oligoprogenitor cells (OPCs) compared to wild type (wt) 
NPCs. Consistent with a more committed progenitor phenotype, lpr NPCs show 
deficiency in mitogenic capacity. We have identified the signaling molecules 
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sonic hedgehog (Shh), Slit2, Hes1, and Noggin as probable mediators of these 
phenomena. 
 
Results 
Lpr NPCs do not express Fas 
In order to confirm that lpr NPCs lack Fas, we stained NPCs with a Fas-specific 
phycoerythrin (PE)-conjugated antibody (or isotype control antibody). Flow 
cytometric analysis demonstrates high levels of Fas surface expression in wt 
NPCs, and no Fas expression in lpr NPCs (Figure 1). 
 
Fas-deficient NPCs have stunted proliferation and neurosphere formation 
Proliferation in response to mitogens and the ability to self-renew are defining 
properties of NPCs. All proliferation experiments were performed in the presence 
of epidermal growth factor (EGF) and fibroblast growth factor (FGF). A 
bromodeoxyuridine (BrDU) assay was used to determine the effects of Fas 
deficency on NPC proliferation. Lpr NPCs showed significantly less BrDU 
incorporation over 16 hours in complete media compared to wt NPCs. Lpr NPCs 
had 18% ±1.6 less proliferation compared to wt (Figure 2a).  
 
Additionally, neurosphere growth in lpr NPCs was abrogated compared to wt 
NPCs (Figure 2b). We performed the neurosphere assay to quantify this 
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difference. In this assay, size of the neurosphere is an indicator of mitogenic or 
proliferative capacity, while neurosphere number is an estimate of the absolute 
total number of putative stem cells (Pluchino, et al., 2008). Over three 
subsequent passages, lpr NPCs developed significantly smaller neurospheres 
than wt (Figure 2c), while the total number of neurospheres remained the same 
(Figure 2d).  
 
To be certain the abrogated proliferative capacity of lpr NPCs was not due to 
altered apoptosis profiles, we also performed UV Live-Dead dye (labeling dead 
cells) and annexin (labeling early apoptotic cells) double-staining on NPCs 
growing in the presence of growth factors (EGF and FGF, similar to proliferation 
experiments). Four days post-cell plating, there was no difference in the amount 
of dead and dying cells in lpr and wt cultures (Figure 2e,f). Quantification of the 
data showed no significant difference between the percentage of live/healthy 
cells in lpr (97%±2.3) and wt (95%±2.6) cells. Therefore, the decrease in 
proliferation cannot be attributed to increased cell death. 
In summary, Fas deficient NPCs are deficient in proliferative properties, 
evidenced by decreased BrDU incorporation and smaller sphere size, but Fas 
expression has no impact on the total number of stem cells (number of 
neurospheres). 
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Enhanced survival of lpr NPCs in growth factor-free conditions 
The ability of NPCs to survive in the absence of growth factors (EGF, FGF) is a 
fundamental issue for transplantation models. If NPCs are unable to survive after 
transplantation due to inadequate levels of growth factors, their beneficial effects 
are negated. Normally, upon growth factor withdrawal in vitro, a large percentage 
of NPCs die (Knight, et al., 2009). We observed significantly higher survival in lpr 
NPCs (42%) compared to wt NPCs (25%) after 48 hours in minimal media (no 
EGF or FGF) using UV/Annexin staining (described above). Therefore, the 
percentage of live/healthy cells in lpr cultures after growth factor withdrawal is 
nearly doubled when compared to wt NPCs (Figure 3a,b). 
 
Lpr NPCs exhibit enhanced differentiation to neuronal and oligoprogenitor cell 
lineages 
One distinguishing feature of NPCs is their capacity to differentiate into the three 
neuroectodermal lineages. We compared lpr and wt NPC lineage marker RNA 
expression for astrocytes (glial fibrillary acidic protein (GFAP), glutamate 
aspartate transporter (GLAST)), OPCs (platelet-derived growth factor receptor-α 
(PDGFRα) and neurons (βIII-tubulin, Doublecortin (Dcx)) using RT-qPCR. After 
two days of differentiation, lpr NPCs expressed significantly higher levels of OPC 
and neuronal markers compared to wt NPCs (Figure 4a).  This trend maintained 
statistical significance after seven days in differentiating media (Figure 4b).  
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We confirmed the enhanced OPC phenotype in lpr NPCs by staining for A2B5, a 
putative OPC cell surface marker, after two days of differentiation. Flow 
cytometric analysis revealed 60% of lpr NPCs were positive for A2B5, while only 
20% of wt NPCs were A2B5-positive (Figure 5a,b). 
 
NPC cell morphology was also confirmed at the protein level using 
immunocytochemistry. Staining for βIII-tubulin and PDGFRα corroborated mRNA 
expression levels, as the percentage of neuronal cells (βIII-tubulin+) and OPCs 
(PDGFRα+) in lpr cultures was double that found in wt (Figure 5c,d).   
Altogether, these data indicate that the absence of Fas enhances NPC 
differentiation to the neuronal and OPC lineages at both the mRNA and protein 
level.  
 
Lpr NPCs exhibit altered levels of neuronal fate specification genes, including 
Shh 
In search of possible mechanisms and pathways controlling the lpr phenotype, 
we ran a “Neurogenesis and Neural Stem Cell” (SA BiosciencesTM) PCR array 
using RNA isolated from wt or lpr NPCs after 7 days of differentiation. Of the >80 
genes tested, four were down-regulated (apolipoprotein E (Apoe), bone 
morphogenetic protein 2 (BMP2), FGF2, S100 calcium binding protein A6 
(S100a6)) and 6 were up-regulated (α-filamin (Flna), hairy and enhancer of split 1 
(Hes1), Neurod1, Noggin, neuronal pentraxin 1 (NptX1), Shh) in lpr compared to 
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wt (Figure 6a). Neurod1, Noggin, and Nptx1 are all genes known to be involved 
in regulating neuronal fate specification. Shh is a major modulator of both 
oligodendrocyte and neuronal differentiation pathways. The Shh antagonist 
BMP2 is down-regulated in lpr NPCs (-3.87 fold, p<0.0012); further indicating 
Shh pathway alterations as a probable mechanism for the altered lpr phenotype. 
Upregulation of Hes1, Noggin, and Shh was confirmed using RT-qPCR (Figure 
6b). To further evaluate the involvement of Shh in the lpr phenotype, we also 
tested expression levels of Gli1, a major regulator and target of Shh signaling. 
Gli1 was up-regulated 3.86-fold (±0.55) in lpr NPCs compared to wt. 
 
Discussion 
There are currently no efficacious treatments for devastating neurodegenerative 
diseases including Alzheimer’s and MS. Therefore, there is a pressing need to 
develop therapeutics that exhibit neuroprotective effects by acting directly on the 
CNS.  NPC therapies represent a novel and promising avenue for developing 
neuroregenerative treatments (Franklin & French-Constant, 2008; Martino & 
Pluchino, 2006).  However, all stem cell therapies currently in development 
ultimately fail in that they are unable to completely repair lost or damaged CNS 
tissue (Blakemore, 2008; Stangel, 2008).  If endogenous or transplanted NPCs 
could be activated to terminally differentiate, CNS damage and consequent long-
term disability could be minimized or even reversed. Therefore, determining 
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modulators of NPC differentation and their mechanisms of action is critical to 
advancing therapies for neurogenenerative disease.  
 
In this study we have elucidated novel mechanisms for Fas-controlled progenitor 
cell behavior. By utilizing a Fas-deficient mutant NPC cell line (lpr), we were able 
to determine the significance of Fas-signaling in NPC survival, self-renewal 
capacity, and differentiation into the three neuroectodermal lineages. Lpr mice 
have a retroviral insertion of poly(A) adenylation signal repeats in the gene for 
Fas (Nagata & Golstein, 1995). This large insertion results in improper splicing 
and truncation of Fas mRNA so that the cells are devoid of protein expression. 
Our study using NPCs isolated from lpr mice is novel in that there has not been 
detailed characterization of how lack of Fas affects NPC stemness and 
differentiation ex vivo.  
 
We showed that lpr NPCs have dramatically decreased cell death upon 
withdrawal of growth factors – a condition that normally induces both significant 
cell death and spontaneous differentiation to astrocytes, neurons, and sparse 
oligodendrocytes. The significance of this discovery is two-fold. First, this 
suggests that Fas manipulation may represent a feasible solution to promote 
NPC viability in harsh environments, including that introduced in exogenous stem 
cell transplantation paradigms.  Second, enhanced survival of NPCs could allow 
for enhanced neuroprotective and immunoregulatory capacity in disease models. 
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We hypothesize that extended survival of lpr NPCs in the absence of growth 
factors increases their capacity for terminal OPC and neuronal differentiation, as 
wild-type NPCs are more likely to die before activating differentiation pathways.  
 
This hypothesis is further supported by our data indicating that lpr NPCs have an 
increased expression of oligoprogenitor cell (OPC) lineage markers and 
enhanced differentiation into mature neurons. Up-regulated OPC marker 
expression in lpr compared to wt NPCs was detected by analyzing mRNA levels 
using RT-qPCR and confirmed using both flow cytometry surface staining (A2B5) 
and confocal microscopy to confirm the OPC phenotype (PDGFRα).  
 
Along with elevated levels of OPC markers, lpr NPCs have elevated levels of 
neuronal-specific lineage markers (BIII-tubulin, doublecortin) both at early (two 
days) and late (seven days) differentiation time points. In addition, the astrocyte-
specific marker GFAP remains unchanged. These data indicate a preferential 
neuronal-fate specification in NPCs lacking Fas. Corroborating these data, lpr 
NPCs show significantly increased expression of genes known to control 
neuronal lineage specification and maturation: Noggin, Neurod1, and Nptx1. We 
identify Shh, Slit2, and Hes1 signaling as putative upstream regulators of this 
neuronally-biased phenotype. Hes1 is a member of the basic helix-loop-helix 
(bHLH) transcriptional repressors that regulate cell proliferation and 
differentiation during embryogenesis.  Levels of Hes1 modulate differentiation of 
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ES cells to neuronal and mesodermal cells and oscillating levels contribute to 
heterogeneous responses from these cells (Kobayashi et al., 2009). Slit2 acts 
through the Roundabout (Robo) receptor and is involved in axon guidance (Lin & 
Isacson, 2006; Patel et al., 2001) and neuronal migration (Wu et al., 1999).  Shh 
is a critical gene involved in patterning during embryogenesis and regulates NPC 
proliferation and neurogenesis (Palma et al., 2005; Zhu et al., 1999). Since the 
absence of functional Fas in our culture system enhanced neuronal 
differentiation, it is possible that active Fas in wt NPCs provides inhibitory signals 
against this lineage development. Whether these inhibitory signals act upon the 
candidate genes identified here requires further study. 
 
Previously, we (Knight et al., 2009) and others (Corsini et al., 2009) have shown 
that activation of Fas via FasL enhances NPC survival.  Additionally, in vivo 
overexpression of FasL increases subventricular zone neurogenesis. An 
explanation for these seemingly contradictory results is that exposure to FasL in 
NPCs enhances both survival and neurogenic pathways (Corsini et al., 2009; 
Knight et al., 2009); however, the presence of a functional Fas system in the 
absence of activating signals (FasL) inhibits these pathways. The latter is 
indicated by our current study since endogenous FasL levels are extremely low 
in our culture system (Knight et al., 2009) and wt NPCs have decreased survival 
and differentiation compared to lpr NPCs – presumably because unactived Fas 
serves an inhibitory role in these phenomena. This suggests a dynamic role for 
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Fas in both NPC fate specification and survival that is dependent on the 
presence or absence of FasL. Taken together, we propose the following 
paradigm for the role of Fas in NPCs. Fas targeting leads to two unique 
physiological processes: first, Fas ablation promotes NPC survival in deprived-
environments and second, Fas ablation promotes increased neuronal and oligo 
differentiation.  
 
Coupled together, Fas manipulation may produce a viable means of modifying 
exogenous stem cell transplantation by overcoming the challenge of cell survival 
under harsh transplantation conditions, while promoting complete integration of 
NPCs into functional neuronal circuits by stimulation of NPC differentiation. The 
Shh signaling pathway, or other molecules identified here, may be a useful target 
in promoting this response. This paradigm offers novel candidates deserving 
further investigation because of their potential to advance NPC transplantation 
therapies. 
 
Conclusion: We have identified Fas as an important modulator of NPC survival, 
differentiation, and proliferation. This study is the first to demonstrate a putative 
mechanistic link between Fas and Shh signaling. Overall, we provide important 
insight into understanding the elusive mechanisms that dictate NPC fate-
determination, an important step in improving NPC-based therapies for 
neurodegenerative disorders.  
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Methods 
NPC Isolation and Culture 
NPCs were isolated from whole brains dissected from 4-day postnatal wild-type 
C57/BL6 or lpr mutant mice (C57/BL6 background). Brains were processed using 
NeuroCult® Enzymatic Dissociation Kit for CNS Tissue (Stem Cell 
Technologies). Resulting single-cell suspension was plated in EGF and FGF 
(both 10 ng/mL) containing complete media (Gibco®Neural Basal Media 
supplemented with B27 and 1:1:2). Neurospheres were chemically dissociated 
(Kit, Stem Cell Technologies) into a single-cell suspension and plated on poly-D 
Lysine and laminin (both Sigma) coated Nunc® flasks or plates for passaging 
and experimentation. Cells were plated at a density of 16,000 cells/mL media 
and grown to confluency (3-4 days) before experimentation or switching to 
minimal media. All experiments were performed on passage-matched wt or lpr 
NPC lines and only cells with passage numbers between 3 and 6 were used. 
Proliferation studies were performed in EGF and FGF containing media, cell 
death studies and early differentiation timepoints were performed in minimal 
media (Neural Basal Media with only B27 and 1:1:2 [penicillin/streptomycin: L-
glutamine: glucose]), and extended differentiation experiments were performed in 
minimal media containing 0.2% FCS (to prevent extensive cell death in the 
absence of growth factors). All cells incubated in 37°C/5% CO2 conditions. 
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Flow Cytometry 
Cells were lifted using 0.05% trypsin/EDTA (Gibco) at 37°C. Trypsin enzyme was 
stopped using 20% FCS/neural basal media after 7 mins. Cells were placed in 
Falcon® tubes (#352058) and then rinsed with 1XPBS and spun at 1400 rpm 
before proceeding with staining. All stains were added to a 100 µL volume cell 
suspension containing approximately 1x106 cells.  
 
Fas receptor stain 
Samples blocked with hamster IgG (50 ug/mL). Samples stained with either anti-
Fas or isotype control (Hamster IgG2, λ1) phycoerythrin (PE)-conjugated 
antibodies (1:30, BD Biosciences). All rinses and dilutions were done with 
1%BSA/1XPBS. All incubations performed at 4°C (15 min for block, 30 min for 
PE-conjugated antibodies). 
 
A2B5 stain  
Biotynlated anti-A2B5 (50 uL, 1:100, BD Pharm) added to each sample. Primary 
antibody incubated for 30 min at 4°C. After rinsing with PBS, Strepavidin-
Phycoerythrin  (100uL, undiluted, BD Pharm) added to each sample and 
incubated for 30min at 4°C. Samples rinsed twice before analyzing on flow.  
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Controls included : no primary and a sample of NPCs  growing in the presence of 
EGF and FGF (to serve as a low percent differentiation negative control). 
 
Death & Apoptosis Assay (UV/Annexin stain) 
UV Live/Dead Dye® and Annexin Alexa Fluor-647 both used according to 
manufacturer instructions (Invitrogen). Briefly, 200 µL of diluted UV dye (2 µL per 
mL 1xPBS) was added to cell suspension containing 10,000 cells/µL. Cells were 
incubated on ice, in the dark, for 30 min. After cells with 1xPBS and aspirating 
the supernatant, 100 uL of diluted Annexin (1 µL per 400 µL HEPES buffer) was 
added to cells. Cells grown in complete media (growth factors present) were 
used as a negative control because >90% of cells in these cultures are 
live/healthy. Cells briefly treated with 3% paraformaldehyde were used as 
positive controls because >90% of cells are dead/dying. 
 
Cell Proliferation: BrDU assay performed according to manufacturer instructions 
(FITC Detection BrdU Flow Cytometry Assay Kit, BD Biosciences). Briefly, cells 
were first pulsed overnight (16 hours) with BrDU and subsequently fixed and 
stained with a FITC-conjugated anti-BrDU antibody for flow analysis.  Cells 
grown in minimal media (no growth factors) were used as a negative control 
because <10% of cells grown in these conditions will stain positive for BrDU 
incorporation. 
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Analysis 
 Flow cytometry analysis was performed by a BD LSRII  flow cytometer equipped 
with 3 lasers (488, helium neon, and UV) and data were analyzed with FlowJo 
software, respectively. 
 
 Neurosphere self-renewal assay 
Single-cell suspensions were plated in uncoated 24-well plates (seeding density 
of 100,000 cells/mL) using NPC media containing EGF and FGF. After 7 days, 2-
3 pictures of random frames from each well (3 wells per cell type) were taken at 
20X using a phase-contrast microscope. After taking pictures, neurospheres 
were dissociated using Neurocult® Chemical Dissociation Kit and then filtered 
through a 40 µm nylon cell strainer (BD FalconTM). Cells were then counted, 
plated as described above, and grown for 7 days before the next passage time 
point was recorded (this same process completed four total times over four 
weeks). Cell circumferences were measured using Neurolucida software.  
 
Immunocytochemistry 
Cells were plated in 24-well plates with poly-D/Laminin coated coverslips and 
grown to confluency. At this point, cells were rinsed and allowed to differentiate 1 
week in minimal media containing 0.2% FCS. For all differentiation markers, 3 
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coverslips were scored per cell line and repeated for at least 3 biological 
replicates. 
 
Stains performed as follows: Cells fixed with Zamboni’s fixative and blocked 
(10%HS/0.1% Triton/0.02% Azide in 1XPBS) for 30 min. Both primary and 
secondary antibodies diluted in block. Block for PDGFRα stain did not include 
triton. Primaries incubated overnight at 4C, while secondary antibodies 
incubated for 1.5 hrs at RT. Cells rinsed 3X between primary and secondary. All 
cells counterstained with Hoechst nuclear stain (1:2000). The following 
antibodies were used: rabbit anti-BIII Tubulin (Sigma, 1:100), rabbit anti-PDGFRα 
(Santa Cruz, 1:50), rabbit anti-GFAP (Dako, 1:1000), goat anti-rabbit Cy3 (1:500, 
Jackson Immunoresearch).  
 
All confocal images were acquired using the “Tile” feature on a Zeiss LSM 510 
META confocal laser microscope. Cells were visualized on the left side of each 
cover slip at 20x magnification, and then the microscope acquired 16 consecutive 
field-of-view images in the form of a 4x4 square (referred to here as a tile). The 
field-of-view was then reset to a visual field directly to the right of this tile, on the 
same horizontal plane as the previous tile. This new tile was acquired, and the 
procedure was repeated until enough tiles were acquired to span the horizontal 
diameter of each coverslip. All cell scoring was performed using ImageJ 
software. Each tile was scored for the number of nuclei present (hoechst positive 
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cells) and the number of cells staining positive for the respective differentiation 
marker. To ensure that we scored every cell spanning the complete horizontal 
diameter, tiles were acquired with slightly overlapping fields of view on the left 
and right sides. Adjacent tiles were then viewed side-by-side and the overlapping 
regions were removed from only one tile, thereby ensuring that every field-of-
view was acquired and that cells in overlapping fields of view were scored only 
once. At least 9 tiles were acquired and tallied per slip, resulting in the total 
acquisition of > 75 individual fields-of-view per coverslip . All data is presented as 
the percentage of positive cells per the total cell count spanning the horizontal 
diameter.  
 
RT-qPCR and Gene Expression Arrays 
Performed as previously described (Knight, et al., 2009). Briefly, RNA was 
extracted from cells using RNeasy® Mini Kit (Qiagen) according to manufacturer 
protocol. For RT-qPCR, cDNA was prepared using Superscript® III First-Strand 
Synthesis Supermix for qRT-PCR. RT-qPCR completed using Taqman® Master 
Mix and applied Biosystems 7500 Fast Software.  Primers were purchased from 
Applied Biosystems (Taqman Assay on Demand). Neurogenesis and Neural 
Stem Cell (PAMM-404) PCR arrays purchased from SA BiosciencesTM and RNA 
samples were processed by UVM Cancer Center DNA Facility. 
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Statistics 
Graphs were created and statistical analyses were run using GraphPad Prism 
software. Student’s t-test or ANOVA with Tukey’s post-test were used to 
determine significance (p-values). 
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Figure 3-1: lpr NPCs lack Fas 
Lpr mice have a large insertion in the Fas gene which results in improper splicing 
and absence of the protein. We confirmed absence of Fas in lpr NPC using a 
phycoerythrin (PE)- conjugated anti-Fas antibody. Background staining was 
assessed using a isotype control IgG antibody (blue line). Unlike wild-type NPCs 
(green line), lpr NPCs (red line) do not express Fas (+ peak completely overlaps 
with isotype control).  Y-axis represents % of maximum staining intensity (arbitray 
units) while the X-axis represents the voltage of positive PE fluorophore staining. 
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Figure 3-2: Abrogated proliferation and sphere growth in lpr NPCs 
(a-f) all experiments performed in complete media (presence of EGF and FGF). 
(a) Cells growing in medium were pulsed overnight with BrDU. Proliferating cells 
were detected using a FITC-conjugated anti-BrDU antibody (*p<0.05, n=4). (b) 
light microscope pictures of 7 day old tertiary neurospheres growing in complete 
media. (c) and (d) Neurosphere self-renewal assay: sphere size and number was 
quantified over 4 passages starting with passage 2 cells. Cells were dissociated 
and re-plated at each passage (i.e. every 7 days). n=6 separate wells from 2 
independent experiments. (c) Neurosphere size quantification using 
Neurolucida® software. Lpr neurospheres were significantly smaller than wild-
type at passage number 3, 4, and 5 (*p<0.05) (d) Quantification of neurosphere 
number. Shown is the average number within 20X phase microscope images (as 
shown in (b)). (e) and (f) representative histograms of cells growing in complete 
media for four days. Y-axis represents dead cells (staining positive for UV 
Live/Dead dye) and X-axis represents apoptotic cells (staing positive for annexin-
AlexaFluor647). The majority of cells are live/healthy (lower left quadrant), with 
no differences between lpr (e) and wt (f) samples. 
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Figure 3-3:Fas-deficient NPCs have increased survival in the absence of 
growth factors 
Cultures were switched to minimal media (no EGF or FGF) for 48 hrs and then 
the apoptosis (Annexin) and death (UV dye) assay was performed and analyzed 
using flow cytometry. (a) Plotted are the percentages of healthy cells, which are 
negative for either stain. n=5 (# independent experiments), error bars represent 
SEM. p<0.01. In representative phase microscope images (b), bright and floating 
bodies represent dead cells (indicated by smaller, red arrows) while attached 
cells with processes represent live/healthy cells (indicated by larger, green 
arrows).  
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Figure 3-4: lpr NPCs are more committed to oligo- and neuronal lineages 
(a) Spontaneous differentiation of lpr cells compared to wt after 2 days in minimal 
media.  (b) Summary of lineage marker results at 2 days (minimal media) and 7 
days (0.1% FCS). Fold changes are lpr expression levels relative to wt.  
Each represented fold difference reached statistical significance (p<0.05, n=5 
independent experiments). Fold changes calculated using 2-ΔΔCt method with β-
actin as the endogenous control gene and wt NPC samples as the calibrator 
(mRNA expression levels set to equal 1). 
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Figure 3-5: lpr NPCs have enhanced differentiation into Neuronal and OPC 
lineages 
(a) Representative fluorescence histogram for A2B5 positivity after 2 days in 
minimal media. Complete media was used as a negative control because no 
differentiation is expected in the presence of growth factors. (b) Quantification of 
A2B5 flow data (n=4 independent experiments, p<0.01). After 3 days of 
differentiation (right columns), lpr NPC still expressed a significantly higher 
amount of A2B5, though overall levels of this marker is decreased in both cell 
types. (c & d) Immunocytochemistry was performed on cells after seven days in 
differentiating media. (c) Differentiation of wt (top panels) and lpr (bottom panels) 
into neurons (βIII-tubulin+ cells, left panels) and OPCs (PDGFRα+ cells, right 
panels). (d) Quantification of IHC data using ImageJ software. Percent positive = 
# lineage marker+/total # of Hoechst+. 12-14 serial photos were taken from 3 
separate coverslips. p<0.05, n=3. 
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Figure 3-6: Upregulation of Shh and neuronal specification genes in lpr 
NPCs 
(a) Shown are genes with significant mRNA fold-changes (out of >80 tested, SA 
BiosciencesTM “Neurogenesis and Neural Stem Cell” PCR Array) in lpr NPCs 
compared to wt NPCs after seven days in differentiation medium. Down-
regulated genes (red font) have been converted to whole numbers via 
1/[fractional fold change]. (b) RT-qPCR confirmation of gene upregulation in lpr 
NPCs after one week in differentiation media. Data are based on 4 biological 
replicates (n=4), all fold changes are significantly above levels in wt cells 
(p<0.01).  
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Abstract 
Immune-neural interactions dictate both lesion formation and repair in multiple 
sclerosis (MS). MS pathogenesis is mediated by the interplay of invading 
immune cells, neurons, glia, and endogenous stores of neural stem/progenitor 
cells (NPCs). However, the signals important in this cross-talk are not well 
defined. We utilized a co-culture method and flow cytometric analysis capable of 
detecting outcomes for both cell types. Here we describe the effects of NPCs on 
three different CD4+ subtypes (Th1, Th2, and Th17) and vice versa. Utilizing lpr 
(Fas receptor-deficient) and gld (Fas ligand-deficient) NPC lines, we further 
define the role of Fas in this neuroimmune cross-talk. We show that only the Th1 
subtype is capable of inducing NPC cell death, and this is independent of Fas 
activation. Conversely, NPCs specifically kill pro-inflammatory Th1 and Th17 
cells in a contact-dependent manner without affecting Th2 survival. Further 
investigation into these effects revealed that FasL expressed by NPCs mediates 
Th17 apoptosis. Additionally NPC/T-cell cross-talk modulates FasL expression in 
both cell types, while Fas receptor levels remains static. These findings illuminate 
the direct neuropathogenic effects of T-cells, as well as help define the 
immunomodulatory capacity of NPCs. We have elucidated novel interactions that 
may be critical in MS pathogenesis.  
 
Introduction 
MS pathogenesis is mediated by complex interactions between invading immune 
cells, neurons, glia, and endogenous stores of neural stem/progenitor cells 
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(NPCs). Though remyelination occurs early in MS disease course, ultimately the 
endogenous stores of NPCs are unable to sustain full neuroprotection and repair 
(Pluchino et al., 2004). Subventricular zone NPCs have the ability to migrate to 
white matter lesions, though their exact neuroregenerative capacity remains 
unknown (Picard-Riera et al., 2002, Menn et al., 2006, Blakemore, 2008). 
Repeated bouts of inflammation have been indicated in altering NPC 
homeostasis, and may contribute to disease pathogenesis (Pluchino et al., 
2008). Both NPC niche architecture and migratory capacity are altered by 
repeated inflammation (Pluchino et al., 2008). A detailed understanding of the 
cross-talk that occurs between NPCs and immune cells is critical for developing 
neuroprotective therapeutics that could be directed at mobilizing or replacing lost 
NPC regenerative capacity. 
 
NPC transplantation therapy has shown significant promise in the animal model 
of MS, experimental autoimmune encephalomyelitis (EAE). Animals receiving 
either intraventricular or intravenous injections show clinical recovery and 
immunopathologically have decreased CNS immune infiltration, inflammation, 
and axonal damage (Einstein et al., 2003, Pluchino et al., 2003, Pluchino et al., 
2009a). The primary mechanism for disease recovery is via bystander 
immunomodulatory functions that decrease inflammation (Pluchino et al., 2005, 
Einstein et al., 2006). Though transplanted NPC clinical effectiveness and 
immunomodulatory capacity is well documented, the exact mechanisms that 
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dictate these effects are not fully understood. NPCs exert immunoregulatory 
functions partially via disruption of activated T-cell expansion. The ability of 
murine and human NPCs to decrease the proliferation of T-lymphocytes has 
been shown both in vitro and in vivo (Aharonowiz et al., 2008, Fainstein et al., 
2008, Pluchino et al., 2009b, Wang et al., 2009). Furthermore, NPCs induce cell 
death specifically in pro-inflammatory Th1 cells via upregulation of various death 
receptors, including Fas (Pluchino et al., 2005). The complex immunoregulatory 
capacity of NPCs is beginning to be uncovered; however, the converse 
interaction – effects of specific T-cell subtypes on NPCs – has not been 
previously described. In this study, we set out to define the critical factors 
involved in the two-way interaction between NPCs and CD4+ T-cell subtypes 
(Th1, Th2, and Th17). To date, no one has studied the communication between 
NPCs and pro-encephalogenic Th17 cells.  
 
Our lab and others have investigated the role of Fas (a member of the TNF 
receptor family) in NPC physiology. Fas has a well-established role in the 
immune system maintaining T-cell homeostasis via apoptotic mechanisms 
(Nagata and Golstein, 1995).  In contrast to the immune system, Fas expression 
and activation has complex and multifaceted roles in NPC biology (Corsini et al., 
2009, Knight et al., 2009). The exact role of Fas/FasL in the nervous system 
appears to be different depending on both the type of cell and maturity stage of 
cell (i.e. functional neuron versus immature NPC). The well-described functions 
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of Fas in the immune system as well as its novel functions in NPCs lead us to 
explore whether Fas was a critical player in immune cell/NPC cross-talk. Here we 
describe novel communications between NPCs and T-cell subtypes. Our data 
show Th1 cells alone induce dose-dependent NPC cell death. NPCs have a two-
fold effect on pro-inflammatory cells. Firstly, they kill Th1 cells in a dose-
dependent and contact-dependent manner.  Secondly, NPCs cause a 
pronounced induction of pro-encephalogenic Th17 cell death via a Fas/Fas 
ligand-dependent mechanism. NPCs have no effect on anti-inflammatory Th2 
survival. Overall, we have elucidated detailed and complex mechanisms 
responsible for NPC immunomodulatory capacity and shed light on the 
previously unexplored ability of T-cells to directly influence NPCs. 
 
Materials and Methods 
NPC Isolation: NPCs were isolated and characterized as previously described 
(Knight et al., 2009). Briefly, brains were dissected from 4-day post-natal C57/Bl6 
mouse pups. NPCs were extracted using NeuroCult® Enzymatic Dissociation Kit 
(Stem Cell Technologies) and plated in complete neural basal media 
(Gibco®Neural Basal Media supplemented with EGF, FGF, B27 and 1:1:2 
[penicillin/streptomycin: L-glutamine: glucose]) and expanded in culture as 
neurospheres. Neurospheres were enzymatically dissociated into a single-cell 
suspension, and then grown as a monolayer on Poly-D-lysine and Laminin (both 
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Invitrogen) coated plates before experimentation. Only NPCs at passage number 
4-6 were used for co-culture experiments. 
NPCs were isolated from wild-type (abbreviated “WT”) C57/BL6 mice, lpr (Fas-
deficient) mutant mice, and gld (fas-ligand deficient) mutant mice. Lpr and gld 
mutant mice are in a C57/Bl6 background. In order to be able to gate the NPC 
population specifically within co-culture flow experiments (see below),  NPCs 
were stably transduced with the DsRED2-mito transgene cloned from a vector 
containing reef coral fluorescent protein as previously described (Spees et al., 
2006). After transduction, DsRED NPCs were sorted using FACS® to obtain a 
purity of 85-95% red cells. Purified cells were expanded before experimentation. 
 
T-cell Isolation and Polarization: Total T-cells were obtained from mechanically 
dissociated lymph nodes (inguinal, mesenteric, periaortic) and spleens of 7-10 
week old wild-type C57/BL6 mice. Blood cells were lysed within spleen 
homogenates using Geye’s solution. CD4+ population was purified using mouse 
CD4+ isolation kit (Miltenyi Biotech) and MACS® magnetic separation columns 
according to manufacturer instructions. To ensure purity, an aliquot of cells was 
subjected to CD4+-surface staining (FITC-conjugated anti-CD4 antibody, BD). All 
T-cell collections used for co-culture experiments had >90% purity.  
Naïve CD4+ cells were plated (1x106 cells/ml) in complete T-cell media (RPMI 
supplemented with Folate, L-glutamate, glucose, 10% FCS, 
penicillin/streptomycin, and β-mercaptoethanol). T-cells were immediately 
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stimulated with soluble 2 µg/ml anti-CD28 and plate-bound anti-CD3 (5 µg/mL ) 
at time of polarization. T-cell polarizations were performed according to 
previously established protocols (Noubade et al., 2007). For polarizations to each 
cell type, cytokines were added as follows: Th1 - 10 µg/mL anti-IL4 & 4 ng/ml IL-
12; Th2 - 10 µg/ml anti-IFNγ & 30 ng/ml IL-4; Th17 - 30 ng/ml IL-6, 1 ng/ml 
TGFβ, 10 µg/ml anti-IFNγ, and 10 µg/mL anti-IL4. After stimulation period (three 
days for Th1 & Th17, four days for Th2), T-cells were re-stimulated with plate 
bound CD3 for 24 hours.  Anti-IFNγ and anti-IL4 were purchased from BD 
Pharmingen, all other cytokines from Peprotech. 
 
ELISA: Reagents and components for ELISA were purchased from R&D. A 96-
well plate was coated overnight with capture antibody (for IL-4, IFN-gamma, or 
IL-17) at 2 ug/mL at room temperature. Plates were washed and blocked with 
block (filtered 1% BSA in 1x PBS) for 1 hour. T-cell supernatants (collected post-
polarization and restimulation) were then added at dilutions of 1:2, 1:4 and 1:8, 
and a standard curve was constructed in the first 3 well columns.  After 2 hours 
at room temperature, the plate washed and detection antibody was added and 
allowed to sit for two hours. Wells were washed, and streptavidin- horseradish 
peroxidase was added for 45 minutes. After another wash,  substrate solution 
(H2O2/tetramethylbenzadine) was added until the reaction developed. Stop 
Solution (2N H2SO4, R&D DY994) was added to each well and the plate was 
read on a microplate reader at 540 nm.  
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Co-Cultures: Single-cell suspension of NPCs were plated at a density of 16,000 
cells/mL in 24-well plates and grown for 3-4 days (~85% confluency) in complete 
neural basal media. At that point, the monolayer of NPCs was rinsed 2X and then 
re-stimulated T-cells were added in either 1:1, 1:3, or 1:5 ratios (NPC: T-cell. All 
co-culture experiments and control samples were cultured in modified T-cell 
media (RPMI, Pen/Strep, L-Glutamate, 5% FCS).  These culture conditions were 
chosen because NPCs did not survive optimally in complete T-cell media (see 
above) and T-cells did not survive in serum free NPC media (data not shown). 
Each well of the 24-well plate contained 0.2x106 NPCs; therefore, 0.2x106, 
0.4x106, or 1x106 T-cells were added to obtain appropriate ratios (1:1, 1:3, and 
1:5, respectively). Total volume of co-cultures was 1mL. NPC or T-cell control 
wells contained only a single cell-type in modified T-cell media. Assays were 
performed after 48 hours of co-culture. Transwell experiments were performed by 
placing T-cells within NUNC™ inserts (0.4 µm membrane). 
 
Assays: Flow cytometric evaluation of apoptotic and dead cells was performed 
with Annexin V Alexa Fluor-647 Conjugate assay and LIVE/DEAD blue-
fluorescent reactive dye kit, respectively (both Invitrogen), according to 
manufacturer instructions. UV Live/Dead dye is a viability dye that stains dead 
cells with compromised cell membranes. It only identifies dead cells, and does 
not discriminate between apoptosis or necrosis. Annexin binds strongly to 
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phosphatidylserine residues on the surface of early apoptotic cells. One of the 
first stages of apoptosis includes loss of the asymmetry of the inner and outer 
layers of the cell membrane (i.e. phosphatidylserine flipping to the exterior 
surface of the cell).  
 
To differentiate between NPC’s and T-cells, T-cells were stained with anti-T-cell 
receptor (TCR)αβ (Cytochrome 5.5 conjugated), and NPCs had been previously 
transduced with the DsRED fluorescent transgene (see above). Dead cells 
commonly stain non-specifically for receptor stains such as TCR. There is a 
small (5-8%) population of TCR+ staining stem cells (Figure 1A), but this staining 
is non-specific because gating exclusively this population reveals only dead cells 
(data not shown). No live NPCs stain positive for TCR+ staining. 
 
Flow Cytometry: Flow cytometry analysis was performed by a BD LSRII flow 
cytometer equipped with 3 lasers (488, helium neon, and UV), and data were 
analyzed with Flow Jo software, respectively.  
 
RT-qPCR: RTqPCR was performed as previously described (Knight et al., 2009). 
Briefly, RNA was extracted from cells using RNeasy® Mini Kit (Qiagen) 
according to manufacturer protocol. For T-cell RNA, supernates from co-cultures 
(containing T-cells floating in suspension) were spun at 1,200 rpm for 6 min; 
supernate was then removed and the T-cell pellet was used for RNA extraction 
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protocol. For NPC RNA, supernates were removed and monolayer cells were 
washed to remove dead cells or T-cells that may have stuck to the surface before 
continuing with RNA extraction protocol. Control cells (either NPCs or T-cells) 
were cultured in modified T-cell media alone. 
 
cDNA was prepared using Superscript® III First-Strand Synthesis Supermix for 
qRT-PCR. RT-qPCR completed using Taqman® Master Mix and applied 
Biosystems 7500 Fast Software.  Primers for Fas and FasL were purchased from 
Applied Biosystems (Taqman Assay on Demand). β-actin was used as an 
endogenous control gene for all experiments. Three biological replicates were 
pipetted in duplicate for each sample. 
 
Data Analysis: All graphs prepared and statistical analyses were run using 
GraphPad® Prism software. Note that “n” refers to the number of independent 
experiments. ANOVA and Bonferroni’s post-test were used to determine 
significance. 
 
Results 
Optimal T-cell Polarization Protocol 
T-cell subtypes are stratified according to their cytokine expression profile. In 
order to ensure T-cells were efficiently polarized to each respective subtype, 
following the polarization and restimulation process, supernatants were collected 
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and stored at -80 for characterization using ELISA. Each sample was subjected 
to a cytokine profile to determine levels of IFN-gamma, IL-4, and IL-17. Only Th1 
cells produced IFN-gamma (Figure 2A), only Th2 cells produced IL-4 (Figure 2B), 
and only Th17 cells produced IL-17 (Figure 2C). 
 
Effects of Immune Cell on NPCs 
To determine the direct impact of each T-cell subtype on NPC viability, we 
analyzed the NPCs specifically within the co-culture based on red 
autofluorescence (DsRED+/TCR- cells; Figure 1A, top gate). NPCs were 
analyzed after a 48-hour co-culture with each polarized and stimulated CD4+ 
subset. Viability was assessed using UV live/dead dye (dead cells and annexin 
(apoptotic cells) co-staining (Figure 1B).  
The percentage of live/healthy NPCs (staining negative for either dye) remained 
unchanged in both Th2 (Figure 3A) and Th17 (Figure 3B) co-cultures, indicating 
that neither Th2 nor Th17 have the capacity to induce NPC apoptosis.  
Conversely, Th1 cells produced a dose-dependent induction of NPC apoptosis, 
indicated by a decreased percentage of live/healthy NPCs with higher T-cell 
ratios (Figure 4A). 1:1, 1:3, and 1:5 Th1 co-cultures reduced the percentage of 
live/healthy NPCs from 87% to 66%, 54%, and 39%, respectively. 
 
To determine whether the ability of Th1 cells to induce NPC death is dependent 
on cell contact or mediated by a secreted factor, we utilized a transwell system 
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where only media is exchanged between cell types. Th1-mediated NPC 
apoptosis is dependent on cell contact, as the effect is negated in transwell co-
cultures (Figure 4B), indicating the phenomenon is likely mediated by a factor 
expressed on the surface of Th1 cells.  
 
In order to assess the importance of NPC Fas-receptor expression in cross-talk 
interactions, co-cultures were performed using wild-type or Fas-deficient (lpr) 
NPCs concurrently. Th1 induction of NPC apoptosis is not mediated by Fas, as 
lpr NPCs had the same amount of death as wild-type NPCs at varying Th1 ratios 
(Figure 4B). 
 
Effects of NPCs on immune cells 
To determine the effects NPCs have on each CD4+ cell type, co-cultures and 
staining were performed as described above, but only the DsRed-/T-cell 
receptor+ population of cells (identified by using a Cy5.5 conjugated anti-TCRαβ 
antibody) was analyzed (Figure 1A, bottom gate). 
NPCs induced dose-dependent death of Th1 cells (Figure 5A), evidence by 
increased Th1 death with higher proportions of NPCs. NPCs decreased the 
viability of Th1 cells by 23% and 20% at 1:1 and 1:3 ratios, respectively. Th1 cell 
viability at the lowest proportion of NPCs (1:5) trended downward, but was not 
statistically significant. NPCs caused a pronounced induction of Th17 cell death, 
and this effect was not dose-dependent (Figure 5B). The percentage of 
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live/healthy Th17 cells was reduced by approximately 45% in NPC co-cultures at 
all ratios. NPCs did not influence Th2 cell survival (Figure 5C). Taken together, 
this data shows NPCs negatively regulate pro-inflammatory Th1 and Th17 cell 
types without effecting anti-inflammatory Th2 cells.  
 
No differences were observed between the ability of wild-type and lpr NPCs to 
affect any T-cell subtype (Figure 5A-C). Therefore, the immunoregulatory 
capacity of NPCs is independent of their Fas-receptor expression.   
 
Mechanism for NPC-mediated Th17 apoptosis  
As Th17 cells are debated to be the most encephalogenic cells in MS, we were 
interested in further investigating the distinctive ability of NPCs to induce Th17 
cell death. Th17 apoptosis was abrogated in transwell cultures (Figure 6), 
indicating this effect was cell-contact dependent. Since our lab previously 
determined the importance of Fas in NPC physiology, and Fas is a major 
regulator of autoreactive T-cell in the immune system, we hypothesized the 
ability of NPCs to kill Th17 cells was mediated by Fas/FasL. In order to test this 
hypothesis, co-cultures were performed with gld (FasL-deficient) NPCs. FasL-
deficient NPCs lost their ability to kill Th17 cells (Figure 6). Therefore, in contrast 
to Fas-receptor expression, FasL expression on NPCs is critical to their ability to 
immunoregulate via Th17 supression. 
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Co-culture influence on Fas/FasL Expression levels 
Expression levels of both the Fas receptor and its cognate ligand (FasL) may 
influence the results of our co-cultures. Futhermore, Fas/FasL expression on 
NPCs/T-cells may change upon exposure to the other cell type.  To explore this 
possibility, mRNA was extracted from NPCs and T-cells either in co-culture or in 
media alone (controls) conditions. This mRNA was subjected to RT-qPCR to 
determine levels of both Fas and FasL. 
 
mRNA expression levels of Fas in both NPCs and T-cells remained unchanged 
in co-culture samples in comparison to controls of each cell type alone. ΔCt 
values for Fas in NPCs remained at 5.90±0.22 in controls and co-cultures, while 
ΔCt values in T-cells remained at 9.02±0.34in all samples (regardless of T-cell 
subtype or culture condition). Therefore, Fas receptor expression remains 
constant in our co-culture system and Fas expression dose not vary in within the 
different T-cell subtypes. 
 
Comparing FasL levels in T-cell subtypes reveals that Th1 cells produce the 
highest levels of FasL (Figure 7A). Th1 T-cells produce approximately 6-fold 
higher levels of FasL compared to Th17 cells. FasL expression levels in Th2 cells 
lies in between those found in Th1 cells and Th17. This differential FasL 
expression between subtypes may explain the fact that Th1 control cultures have 
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significantly more baseline cell death compared to Th17 cultures. Th1 and Th17 
T-cell alone control cultures have 60% and 80% live/healthy cells, respectively 
(Figure 5A,B). Death induction via T-cell expressed FasL is a well characterized 
mode of autoregulation and maintaining homeostasis within the immune system 
(Nagata and Golstein, 1995). 
 
Co-cultures with Th1 cells dramatically increase the NPC expression of FasL in a 
dose dependent manner (Figure 7B). The 1:1 ratio of NPCs to T-cells increased 
NPC FasL expression 16-fold compared to NPC control cultures, while the 1:3 
ratio increased expression approximately 30-fold. Th17 cells appear to have a 
more modest effect on NPC FasL expression, as significant effects were only 
seen at the 1:3 ratio. 1:3 co-cultures enhanced NPC FasL expression levels by a 
factor of 2.3±0.22 (p<0.05).  
 
In contrast to NPCs, FasL levels in Th17 cells is decreased in co-cultures 
compared to Th17 control samples (Figure 7C). This effect is dose-dependent, 
as the 1:3 ratio (1NPC: 3TC) exhibited a 2.2-fold (±0.17) decrease in Th17 FasL 
expression and the 1:1 ratio (1NPC: 1TC) decreased FasL expression 4.2-fold 
(±0.29). Since FasL can be toxic to neurons and oligodendrocytes (Li et al., 
2002, Giuliani et al., 2003), NPC-mediated downregulation of FasL in 
proinflammatory T-cells could be a novel mechanism for immunomodualtion and 
supporting neuroprotection. Th1 FasL levels trended downwards in co-cultures in 
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comparison to Th1 controls, however this difference was not statistically 
significant at either ratio. 
 
Discussion 
This study demonstrates that there is direct influence of inflammatory cells on 
NPCs. This phenomenon could reflect critical interactions with endogenous 
NPCs in MS disease lesions. Our work is novel in that it is the first to investigate 
the effects of specific T-cell subtypes on NPCs. T-cell effects on NPCs were only 
observed in Th1/NPC co-cultures, where Th1 cells caused dose-dependent NPC 
apoptosis. These effects are cell contact-dependent and Fas-independent. Since 
Th1-mediated NPC death requires cell contact, it is likely that a factor expressed 
on the Th1 cell surface induced this effect. As Th1 cells were the only CD4+ 
subtype to induce NPC death, this factor must be specific to Th1 cells. Further 
investigation into this mechanism will shed further light on how inflammatory cells 
can directly damage the endogenous NPC niche.  
 
Secondly, our results present a detailed mechanism for the robust 
immunoregulatory properties of NPCs. Overall, our data indicate that the 
immunomodulatory capacity of NPCs seen in previous EAE studies likely stems 
from their ability to selectively delete pro-inflammatory T-cells, as opposed to 
supporting anti-inflammatory Th2 cells (Figure 8).  We found that NPCs 
selectively kill pro-inflammatory Th1 and Th17 cells, and do not influence Th2 cell 
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death. Interestingly, interactions with Th1 T-cells enhanced FasL expression in 
NPCs in a dose-dependent manner. A smaller induction of FasL was also seen in 
Th17 co-cultures at the higher concentration. This phenomenon may serve to 
enhance NPC-mediated killing of proinflamatorry T-cells, as higher 
concentrations of T-cells signal to the NPC that more FasL is required for 
immunomodulatory efficiency. Both Th1 and Th17 cells are considered to be the 
main mediators of disease pathogenesis in MS. In our study, NPCs were able to 
induced dose-dependent apoptosis in Th1 cells. This result is in line with 
Pluchino’s work that showed NPCs induce selective Th1 apoptosis without 
influencing Th2 cells (Pluchino et al., 2005). This effect was modulated by up-
regulation of specific death receptors (FasL, TRAIL, and APO3L) on the surface 
of NPCs (Pluchino et al., 2005).  The beneficial anti-inflammatory effects of NPCs 
paired with their capacity to home specifically to lesions within the CNS (Ben-Hur 
et al., 2003, Pluchino and Martino, 2005) make them a promising candidate for 
therapeutic intervention. The fact that NPCs follow chemokine and cytokine 
gradients to enter the damaged CNS (Pluchino et al., 2005, Pluchino et al., 
2009a), along with their ability to persist for long periods of time within the brain 
parenchyma (Pluchino et al., 2009a),may allow for enhanced, targeted 
neuroprotection compared to currently used systemic therapies.  
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Our data show NPCs induce a dramatic induction of pro-encephalogenic Th17 
cell death. This effect is cell-contact dependent and is mediated via NPC 
expression of FasL.  Robust deletion of Th17 cells by FasL expressed on the 
NPC surface is a novel mechanism for NPCs supporting an anti-inflammatory 
environment and neuroprotective functions. Our findings that NPCs can also 
down-regulate FasL expression on Th17 cells may further contribute to 
neuroprotection since T-cell expression of FasL has been associated with 
neuronal and oligodendrocyte death (Li et al., 2002, Giuliani et al., 2003). These 
results are speculative, however as cell preparations from which mRNA was 
isolated may include dead NPC cell mRNA. NPC effects on Th17 cells  have the 
most prominent potential implications for MS, as the Th17 subtype is now 
considered central to the development and progression of inflammatory lesions. 
Most data supporting this view comes from EAE studies. EAE can be induced by 
passive transfer of IL-17 producing, activated CD4+ cells (Langrish et al., 2005). 
Mice deficient in IL-12 or IFNγ, factors known to suppress IL-17 production, 
exhibit exacerbated EAE (Murphy et al., 2003, Langrish et al., 2005). 
Furthermore, blocking the p40 subunit of the IL-17 receptor with administered 
antibodies decreases EAE severity (Cua et al., 2003, 't Hart et al., 2005). Support 
for these findings having clinical importance in humans comes from MS lesion 
studies. IL17+ cells have been found in active MS lesions (Tzartos et al., 2008), 
and receptors for Th17 cytokines (IL-17 and IL-22) have been identified within 
MS lesions (Kebir et al., 2007). Both IL-6, which promotes Th17 differentiation, 
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and IL-17 gene transcripts are increased in acute lesions (Lock et al., 2002). If it 
is true that Th17 cells are critical in MS pathogenesis, our data indicate that 
NPCs may be particularly effective as a therapeutic approach because they can 
specifically target and delete this encephalogenic cell type.  
 
Fas-induced apoptosis via FasL is a well established mechanism of maintaining 
homeostasis within the immune system (Nagata and Golstein, 1995). Unlike 
NPCs, T-cells are very sensitive to FasL induced cell death (Knight et al., 2009). 
It is likely that FasL expressed by the T-cells themselves results in some T-cell 
apoptosis in our co-culture system.  As 20% of Th17, 25% of Th2, and 40% of 
Th1 cells are dead/dying at baseline (T-cell alone controls- See Figure 5), it is 
plausible to assume at least some of this death is caused by T-cell expression of 
FasL. Considering Th1 cells express much higher levels of FasL compared to 
either Th2 or Th17 (Figure 7A), this may be an explanation for the increased 
death seen in Th1 control cultures (compare Figure 5A to 5B or C). 
Interactions between endogenous NPC populations and invading immune cells 
may have a critical role in both ameliorating inflammatory damage and repairing 
damaged tissue in MS. Recent evidence suggests that subventricular zone 
(SVZ)-derived NPCs may contribute to remyelination in both inflammatory and 
toxic demyelinating rodent models (Picard-Riera et al., 2002, Menn et al., 2006, 
Blakemore, 2008). Since inflammatory demyelinating lesions accumulate over 
time in the SVZ of MS patients, it can be hypothesized that an alteration of the 
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functionality of SVZ-resident NPCs may contribute to remyelination failure in MS. 
The main potentially clinically relevant point of contact for NPC/immune cell 
cross-talk is the MS lesion site. Both SVZ and spinal cord NPC have the ability to 
migrate to lesion sites in EAE (Picard-Riera et al., 2002, Brundin et al., 2003). 
Furthermore, cells positive for the NPC marker NG2 have been identified within 
lesion sites in MS patient tissue (Chang et al., 2000). On the immune side of 
cross-talk, there is striking evidence for CD4+ infiltrates in acute MS lesions, and 
to a lesser extent in chronic lesions (Stadelmann and Brück, 2008, Tzartos et al., 
2008). Additionally, both T- and B-cell infiltrates correlate with activity in 
demyelinating lesions (Frischer et al., 2009). Importantly, neurodegeneration 
correlates with inflammatory markers throughout early and late stages of disease 
(Frischer et al., 2009). Therefore, understanding the neural-immune interface is 
crucial for developing strategies that can mitigate the axonal damage that occurs 
during relapsing-remitting disease, and also the chronic neurodegeneration that 
occurs in secondary-progressive phases.  Although our study is limited in that we 
present only in vitro data, an advantage of this system is the ability to articulate 
the communications between specific cell types and elucidate the factors that 
dictate these interactions. Since our co-culture system serves as a model for 
phenomena that occur within the inflamed CNS, the neuroimmune cross-talk and 
factors described here may have relevance for therapeutic intervention. 
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In summary, elucidating the specific signals that dictate communications at the 
neural-immune interface will allow for greater understanding of both NPC 
therapeutic potential and MS pathogenesis. Using our co-culture system, we 
have characterized novel interactions between NPCs and specific CD4+ T-cell 
subtypes. We have identified a previously undescribed mode of NPC 
immunoregulation via FasL-dependent deletion of Th17 cells, and are the first to 
report that Th1-cells in particular can directly harm NPCs. Cross-talk between 
NPCs and TCs also modulates the production of FasL in either cell type: co-
culture leads to increased FasL in NPCs, but decreased FasL in Th17 cells. This 
study sheds light on neuroimmune communication by identifying novel 
mechanisms mediating cross-talk between NPCs and T-cells.   
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Figure 4-1: Four color flow cytometry analysis 
 A. The Y-axis shows DSRed positive cells (autofluorescent NPCs). The X-axis 
shows Cy5.5 positive cells (T-cell receptor stained). NPC gates and T-cell gates 
were created from the two populations. B. Representative sample analysis of 
dead (UV+) and apoptotic (Annexin-647+) cells from gated populations in (A). 
Shown are control samples (top panels) and co-culture samples (bottom panels) 
from a representative Th17 co-culture experiment. Subsequent graphs within this 
article show percentage of live/healthy cells (lower left quadrant, negative for 
either dye).  
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Figure 4-2: Confirmation of the Th1, Th2, and Th17 subtypes following 
polarization 
Supernates from T-cell cultures were collected at the end of the polarization/re-
stimulation process and ELISA for characteristic cytokines was performed. 
Shown are average cytokine levels for each subtype: (A) Th1, (B) Th2, and (C) 
Th17. n=5 representative experiments. 
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Figure 4-3: Th2 and Th17 T-cells do not induce NPC death  
Results from 48hr co-culture experiments. Activated and polarized T-cells were 
added in excess to NPCs growing in a monolayer (80% confluency) in modified 
RPMI media. After the co-culture period, flow cytometry UV/Annexin staining (for 
dead and apoptotic cells, respectively) was performed on Th2 cultures (A) or 
Th17 cultures (B). Shown are the percentage of live/healthy NPCs (negative for 
UV and Annexin dyes, see Figure 1). n=6. LPR= Fas receptor deficient NPCs.  
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Figure 4-4: Th1 induced NPC death is dose- and contact-dependent  
(A) Results from Th1 co-cultures performed as described in Figure 1. NPC 
viability decreases as ratio of T-cells increases. n= 4 (B) Th1 co-cultures 
performed with transwell inserts (0.4um pores; prevents cell-contact while 
allowing media exchange) or lpr NPCs. Lpr NPCs lack Fas receptor expression, 
therefore the observed Th1-induced death is Fas-independent. n=3, *p<0.05, 
**p<0.01  
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Figure 4-5: NPCs induce pro-inflammatory Th1 and Th17 cell-death, but not 
Th2 
(A-C) T-cell viability data from co-cultures as described in Figure 1. Co-cultures 
were perfomed using wild-type (WT) or lpr NPCs simultaneously so that the role 
of Fas in observed effects could be determined. (A) dose-dependent Th1 cell 
death. n=4 (B) Striking induction of Th17 cell death. n=7 (C) absence of death 
induction in Th2 co-cultures. n=6, *p<0.05; **p<0.01. TC=T-cell.  
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Figure 4-6: NPC-induced Th17 apoptosis is via cell-contact dependent 
Fas/FasL interactions  
Th17 co-cultures were performed with wild-type NPCs in either cell contact or 
transwell conditions.  In other co-cultures, gld NPCs, which do not express FasL, 
were used in lieu of wild-type NPCs. n=4, p<0.01 
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Figure 4-7: Co-culture effects on FasL Expression in different cell types 
All relative gene expression values were calculated using 2-ΔΔCt method, β-actin 
as the endogenous control gene, and choosing the appropriate calibrating 
samples. For calibrating samples, (Th17 cells in (A); NPC control in (B), and T-
cell control in (C)) relative expression is set to equal 1, and all other values are 
expressed as a fold change relative to that. (A) FasL expression was determined 
in T-cell control samples (RPMI media alone). Shown is fold increase of FasL in 
Th1 and Th2 cells compared to Th17 cells (control/complete RPMI samples) (B) 
Relative FasL mRNA levels in NPCs in co-culture compared to NPC alone 
controls. (C) Relative FasL mRNA levels in Th1 and Th17 cells at two different 
NPC:TC ratios compared to T-cell alone controls. *p<0.05, **p<0.01; n=4.  
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Figure 4-8: Summary-  Mechanism for NPC immunomodulatory functions 
The capacity of NPCs to regulate inflammatory niches is primarily through direct 
induction of encephalogenic Th1 and Th17 T-cell death. 
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CHAPTER 5: SUMMARY & CONCLUSIONS 
 
 
MS is a chronic, debilitating disease characterized by CNS inflammatory lesions 
and a variable clinical course. Autoreactive immune cells drive demyelination and 
resulting axonal degradation. This forms the cellular and molecular basis for the 
majority of symptoms MS patients experience. MS generally begins as a 
relapsing-remitting disease, but later becomes progressive without remission. 
Repeated bouts of inflammatory episodes are thought to contribute to disease 
pathology by damaging the endogenous NPC compartment and thus interfering 
with NPC-mediated repair. Therefore, the introduction of new, undamaged cells 
via NPC transplantation is a novel and promising avenue for treating MS 
because exogenously administered NPCs may be able to circumvent damaged 
CNS NPC niches and promote neuroregeneration.  
 
Although NPC transplantation produces significant clinical improvement the main 
animal model of MS (EAE), there are several pitfalls with this therapy that need 
to be addressed before clinical translation in a human population possible. 
Specifically, low post-transplantation survival of injected cells and ineffective 
differentiation/integration into CNS tissue are two key issues. As opposed to cell-
replacement, originally hypothesized to be the main mechanism NPCs would 
improve clinical symptoms, NPCs alter disease course via bystander functions 
such as secretion of neuroprotective factors and down-modulation of immune-
mediated inflammation. Despite the significant data indicating that NPCs are 
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effective at treating EAE via bystander mechanisms, detailed knowledge 
regarding the key modulators of NPC survival, differentiation, and immune-cell 
interactions is lacking. Addressing these gaps is critical to advancing NPC 
therapeutic strategies as well as understanding MS disease progression.  
 
The goal of my dissertation research was to characterize the roles of Fas in NPC 
survival, differentiation, and T-cell cross-talk. Fas, a member of the tumor 
necrosis superfamily of death receptors, has well-characterized functions in the 
immune system and in developmental programmed cell death in the CNS. In 
addition to apoptosis-mediating functions, Fas has diverse roles in various cell 
types from T-cells to neurons to endothelial cells. Despite reports that NPCs 
express Fas, its functions in this specific cell type were previously unelucidated. 
Overall, this dissertation reveals Fas functions in NPCs in vitro (Specific Aim 1), 
advances this understanding to how these mechanisms are important in NPC/T-
cell cross-talk (Specific Aim 2), and finally tests this paradigm in vivo (Specific 
Aim 3). 
 
The Fas system plays a multifaceted role in NPC biology 
 
Using recombinant Fas ligand (FasL) I found that activation of Fas receptor (Fas) 
increases NPC survival in normally death-inducing conditions (growth-factor 
deprived medium). The increase in NPC survival results from Fas-mediated 
inhibition of apoptosis as opposed to a promotion of proliferation. This is in stark 
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contrast to T-cells, wherein activation of Fas via FasL results in formation of the 
death-inducing signaling complex (DISC) which activates caspase-3 to induce 
apoptosis. Since flice-like inhibitory protein (FLIP) upregulation in other cell types 
has been associated with resistance to Fas-mediated cell death, I examined FLIP 
levels in treated or control NPCs. Unlike T-cells, cleaved/DISC associated FLIP 
was not detected in NPCs. This, along with caspase-3 and -8 levels remaining 
constant, suggests that Fas in NPCs does not signal through DISC. Therefore, 
some other signaling molecules must mediate the anti-apoptotic effects of FasL.  
 
In order to determine which pathways may mediate these effects, I ran a 
screening “Apoptosis” RT2 ProfilerTM PCR array comprehensive of apoptosis-
associated genes from several distinct signaling pathways. Of the over 80 genes 
tested, Birc3 - a member of the inhibitor of apoptosis (IAP) family of proteins - 
was the only anti-apoptotic gene with significant fold-upregulation upon FasL 
treatment. My study was the first to correlate Birc3 levels with Fas activation in 
any cell type, and the first to implicate Birc3 in NPC pro-survival. To ensure the 
anti-apoptotic effects are mediated via Fas and not another non-specifc pathway, 
I treated Fas receptor-deficient (lpr) NPCs with FasL. Birc3 levels remained 
unchanged in lpr NPCs treated with FasL, confirming FasL is working specifically 
through Fas in wild-type NPCs. 
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In order to further characterize the role of Fas in NPC survival, differentiation, 
and proliferation I utilized our lpr (Fas-Deficient) line of NPCs. In comparison to 
wild-type NPCs, lpr NPCs exhibit enhanced differentiation to neuronal and oligo-
lineages. I confirmed the altered differentiation capacity of lpr NPCs using RT-
qPCR, flow cytometry surface staining (A2B5, putative OPC marker), and 
immunocytochemistry (βIII-tubulin and PDGFRα). The exact mechanisms 
responsible for this difference in multipotentiality remains to be elucidated. The 
“Neurogeneis and Neural Stem Cell” focused RT2 ProfilerTM PCR array identified 
Shh, Noggin, and Hes1 as potential modulators of the enhanced neuronal and 
OPC fate-specification seen in lpr NPCs. Levels of these particular gene 
transcripts are significantly upregulated in lpr NPCs compared to wild-type after 7 
days in differentiating media.  Lpr NPCs also have abrogated proliferative 
capacity compared to wild type NPCs demonstrated by both decreased BrDU 
incorporation and smaller sphere size over several passages. Lastly, I found that 
lpr NPCs have enhanced survival compared to wild type NPCs in growth factor-
deprived conditions. This improved survival in a stress-inducing environment, 
may actually contribute to the enhanced differentiation abilities of lpr NPCs. It is 
possible that an increased percentage of cells surviving in the absence of growth 
factors allows for a higher number of cells to activate differentiation pathways.   
Overall, my data suggest that Fas plays an important, multifaceted role in 
NPC survival, differentiation, and proliferation (Figure 5-1). 
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Figure 5-1: Roles of Fas in neural progenitor cells 
The exact role of Fas in NPC survival, proliferation, and differentiation is 
dependent on both environmental cues (FasL) and cell expression of Fas. 
Activation of Fas via FasL results in decreased apoptosis by upregulation of the 
anti-apoptotic protein Birc3. Absence of Fas results in upregulation of 
compensatory signaling pathways that result in decreased apoptosis, decreased 
proliferation, and increased differentiation to neuronal and OPC phenotypes.  
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The presence of a functional Fas receptor on NPCs as well as the availability of 
activating signals (FasL) contribute to determining effect of the Fas system on 
NPC fate. From my first experiments, I found activation of Fas using recombinant 
FasL results in increased survival of NPCs in a growth factor-deficient 
environment and that FasL treatment does not effect either NPC proliferation or 
differentiation capacity. Based on this data I originally hypothesized that, since 
FasL acts as a survival signal for NPCs, the absence of Fas should result in 
increased NPC death without affecting differentiation or proliferative capacity. 
However, I found that lpr (Fas-deficient) NPCs exhibit increased survival, 
increased differentiation to neuronal and oligoprotenitor phenotypes, and 
decreased proliferation compared to wild-type NPCs.  
 
There are two possible explanations for these results. First, it is probable that 
functional Fas in the absence of FasL is not “silent,” but actually inhibits the 
differentiation of NPCs (Figure 5-2a). Other factors in the media may non-
specifically activate Fas and promote alternate, inhibitory signaling cascades in 
NPCs. Thus, lpr NPCs exhibit increased differentiation, in comparison to wild-
type NPCs, because they lack this inhibitory signal. Furthermore, in the absence 
of FasL signaling cells to survive, pro-apoptotic “default” pathways may 
predominate within Fas-expressing wild-type NPCs. 
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Figure 5-2: Predominating signals in wild-type NPCs  
Unactivated Fas (scenario a.) inhibits differentiation to OPC and neuronal 
phenotypes while allowing default apoptotic pathways to predominate. These 
outcomes are likely mediated via Fas interacting with currently unknown adaptor 
molecules and/or various signaling pathways (red arrows). This serves as a 
possible explanation as to why Fas-deficient (lpr) NPCs exhibit both increased 
differentiation and decreased apoptosis (they lack both signals). However, 
activation of Fas via FasL (scenario b.) results in predominating signaling 
cascades (involving Birc3) which ultimately result in increased NPC survival (by 
inhibiting apoptosis).  
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In other words, if NPCs are exposed to FasL, survival will be increased (Figure 5-
2b); however, if NPCs reside in a FasL-deficient environment, a functional Fas 
system is detrimental to survival (Figure 5-2a). This would explain why lpr NPCs 
have increased survival in comparison to wild-type, as FasL levels are essentially 
undetectable in serum-free cultures (Knight, 2009).  
 
Secondly, it is also possible that the altered phenotype seen in lpr NPCs is due to 
abnormal embryological development resulting from an absence of Fas. Lack of 
Fas in developing NPCs may induce compensatory pathways that dictate the 
altered phenotype exhibited by lpr NPCs. In order to determine if differences 
observed in the lpr NPC cell line are due to developmental abnormalities or the 
absence of Fas itself, one would have to re-introduce Fas to lpr NPCs and see if 
this reverts the mutant NPC line back to the wild-type phenotype. If re-
introduction of Fas to lpr NPCs does not alter their characteristics as expected, 
then developmental alterations are responsible the reported results.  If this is the 
case, it would be of interest to explore what developed compensatory pathways 
drive the increased survival and differentiation profiles in lpr NPCs because these 
signaling pathways/molecules represent novel targets for controlling NPC fate. 
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NPCs can specifically target and kill pro-inflammatory T-cells and FasL is a 
critical mediator of this process 
 
Since Fas plays a complex, multifaceted role in NPC fate-determination and it 
also has well-characterized functions regulating homeostasis in the immune 
system (by deleting autoreactive T-cells via FasL mediated apoptosis), I 
hypothesized that Fas is an important mediator of NPC/immune cell cross-talk. In 
order to test this hypothesis, I developed a co-culture system where I could 
determine outcomes of both NPCs and T-cells. Because CD4+ T-cells are 
considered the main mediators of disease pathogenesis MS, I focused on three 
CD4+ T-cell subsets in my study (Th1, Th17, and Th2). For each experiment I 
used lpr NPC co-cultures (in addition to wild-type) in order to determine the role 
of Fas expression in any observed interaction. My research is novel in two 
respects; first, no former literature details the effect specific T-cell subtypes have 
on NPCs. Secondly, I am the first to examine the interaction between NPCs and 
pro-encephalogenic Th17 cells.  
 
Effects of T-cells on NPCs 
Of the CD4+ T-cells tested, only Th1 cells are able to directly induce NPC cell 
death. This apoptosis occurs in a contact-dependent and Fas-independent 
manner.  It is of interest to elucidate which surface molecule on Th1 cells has the 
ability to kill NPCs because antagonizing this process represents a novel 
therapeutic target. Th1-mediated NPC death may contribute to infiltrating 
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immune cells impeding the endogenous stem cell compartment and promoting 
neurodegenerative processes 
 
Effects of NPCs on T-cells 
The ability of NPCs to inhibit pro-inflammatory Th17 cells is two-fold. First, NPCs 
induce significant Th17 cell death. These effects are mediated via cell contact 
and are not altered by lack of Fas expression in NPCs (i.g. lpr and wild-type 
NPCs produced similar results). In contrast to expression of the receptor, I found 
that expression of the cognant ligand (FasL) on NPCs is needed in order for 
NPC-mediated Th17 apoptosis to occur. This was demonstrated by abrogation of 
Th17 cell death when co-cultures where performed with FasL-deficient (gld) 
NPCs. Secondly, co-culture with NPCs decreases the expression of FasL on 
Th17 cells. Since FasL has been shown to be toxic to neurons and 
oligodendrocytes, preventing the overproduction of FasL within the CNS is most 
likely beneficial (Giuliani et al., 2003; W. Li et al., 2002). Therefore, NPC 
modulation of Th17 FasL production may be another important mechanism for 
immunoregulation in favor of neuroprotection.  
 
Futhermore, my study supports prior data that NPCs can specifically kill pro-
inflammatory Th1 T-cells, but not anti-inflammatory Th2 cells (Pluchino et al., 
2005). Overall, my data indicate that the major mechanism for NPC 
immunoregulation is inhibition of pro-inflammatory T-cells (Figure 5-3). However, 
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unlike NPC FasL expression, which is critical to NPC-induced encephalogenic T-
cell death, NPC expression of Fas receptor does not influence their 
immunomodulatory capacity since lpr and wild-type NPCs induced pro-
inflammatory T-cell death to the same extent.  
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Figure 5-3: Mechanism for NPC immunomodulatory functions  
The capacity of NPCs to regulate inflammatory niches is primarily through direct 
induction of encephalogenic Th1 and Th17 T-cell death. *From Knight, et al., 
accepted to Journal of the Neurological Sciences (Chapter 4). 
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NPC Fas receptor expression does not impact transplantation efficacy  
 
Based on results detailed in Chapter 3, I hypothesized that the enhanced 
differentiation and survival capacities of lpr NPCs may contribute to better post-
transplantation survival and CNS integration, consequently leading to improved 
clinical outcomes in EAE. To test this hypothesis, we injected either wild-type or 
lpr NPCs into mice during the height of EAE inflammation (14 days post-
immunization). Clinical scores for NPC or vehicle (PBS) control injected mice 
were recorded over acute and chronic time points. Mice brains and spinal cords 
were analyzed for inflammatory infiltrate via immunohistochemical analysis for 
CD45+ cells. GFP+ NPCs were visualized in periventricular and parencymal areas 
of the brain as well as in the spinal cord.  
 
Though the number of NPCs entering the CNS was scarce, the NPCs exhibited a 
strong capacity for localizing to inflammatory sites (Appendix A, Figure A-2). Both 
lpr and wild-type NPCs decreased EAE clinical scores to the same extent at the 
acute timepoint (Appendix A, Figure A-3 & A-4). Furthermore, amount of CNS 
infiltrating immune cells was decreased equally in both lpr and wild-type NPC 
injected groups compared to controls (Figure A-5). For the chronic timepoint, 
average clinical scores in NPC treated groups were not significantly different 
compared to PBS control mice (Figure A-3). However, the cumulative disease 
score was much lower in both lpr and wild-type treated groups compared to PBS 
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controls (Table A-1). All relevant EAE data is summarized in Table A-1. Taken 
together, these results lead me to reject my original hypothesis. 
 
Even though lpr NPCs have significantly higher differentiation and decreased 
apoptosis compared to wild-type NPCs in vitro, this did not translate to promoting 
terminal differentiation and post-transplantation survival in vivo. It is possible that 
there are environmental factors unique to the CNS compartment which prevents 
the differentiation of transplanted NPCs, regardless of their inherent 
differentiation capacities. Conceivably, inflammation itself may contribute to the 
inhibition of differentiation. This hypothesis is supported by numerous prior 
reports of injected NPCs remaining in a “progenitor,” undifferentiated state 
(Einstein et al., 2006; Einstein et al., 2003; Pluchino et al., 2005). Identifying what 
molecules are responsible for inhibiting NPC differentiation in vivo warrants 
further investigation because modulating these signals could promote 
oligodendrocyte production and remyelination, ultimately resulting in more 
effective CNS repair.  
 
Since inflammation itself may prevent terminal differentiation and integration of 
transplanted NPCs, it would be of interest to test the ability of lpr NPCs to 
effectively differentiate to oligodendroctyes in an in vivo model that lacks chronic 
CNS inflammation. The cuprizone model of toxic demyelination would be a viable 
alternative. Because, in contrast to EAE, the cuprizone model lacks inflammatory 
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confounding factors and this model is characterized by extensive demyelination 
(Torkildsen, 2008). However, a downside of cuprizone-induced demyelination is 
the lack of clinical manifestations (Torkildsen, 2008). Furthermore, since we are 
interested in developing NPCs as a therapy for MS, a complex disease wherein 
inflammation and neurodegeneration are intimately associated, EAE remains the 
most relevant animal model.  
 
I originally hypothesized that the increased survival exhibited by lpr NPCs would 
result in more abundant NPC/immune cell interactions, thus improving their 
immunoregulatory capacity and ability to improve EAE disease course. As 
explained above, this hypothesis was not supported by my data. In lieu of my 
former hypothesis, I would propose the following explanation. Since only a very 
small number of NPCs actually enter the CNS and are required for clinical 
improvement, survival differences between lpr and wild-type NPCs become 
insignificant. Furthermore, since my co-culture data reveal that the 
immunomodulatory capacity of NPCs is not affected by their Fas-expression and 
considering peripheral/ “bystander” immunoregulatory functions of NPCs are 
most likely primarily responsible for improving disease outcomes (Ben-Hur, 2008; 
Pluchino & Martino, 2008) – it is not surprising that lpr and wild-type NPCs have 
the same efficacy in EAE.  
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Concluding Remarks 
Although Fas plays multifaceted roles in NPC fate specification in vitro, 
modulation of the Fas receptor proved not to be an effective method for 
improving transplantation efficacy. Despite this, NPC transplantation therapy 
remains a viable approach in development for MS. In particular, the ability of 
NPCs to home to areas of inflammation within the CNS may provide substantial 
benefit compared to currently utilized peripheral immunotherapies. Little evidence 
exists for any currently used MS drug crossing the blood brain barrier. If NPCs 
are able to localize to CNS lesions and exert regenerative and 
immunomodulatory effects directly at the site damage, then NPCs may be able to 
more effectively prevent the chronic neurodegeneration that occurs in MS despite 
aggressive pharmacotherapy. 
 
My data shows NPCs can specifically regulate Th17 T-cells via direct apoptosis 
as well as inhibiting FasL production. These findings are important and give 
further credence for the potential of NPCs as a novel therapy for MS because 
Th17 cells are regarded as the major, extremely pro-encephalogenic mediators 
of CNS damage. Since immune interactions driving MS pathology are extremely 
complex and are required for many reparative processes to take place, it is 
important to find a therapy that can specifically target pro-inflammatory cells 
without altering anti-inflammatory, reparative processes. NPCs seem ideal for 
this since they specifically kill Th1 and Th17 cells without affecting Th2 survival. 
Because of NPC’s robust immunomodulatory capacity, they may provide 
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significant benefit during both the relapsing-remitting and the neurodegenerative 
phases of MS considering immunological compromise is present over the entire 
clinical course (Frischer et al., 2009).  
 
Some major questions remain for the viability of NPC transplantation therapies. 
1) What factors can be altered either in vivo or in vitro to enhance NPC 
differentiation and terminal integration? 2) If NPC differentiation can be improved, 
would this positively affect clinical outcomes? Both questions warrant future 
investigation. It is entirely possible that the only viable mechanism for NPCs to 
improve MS is via bystander immunoregulation. Further investigation into 
NPC/immune cell cross-talk will reveal other factors important in this 
communication and holds the possibility for determining novel therapeutic 
targets. If we can better understand, and change, how invading T-cells influence 
the endogenous NPC compartment we may be able to supersede the need to 
transplant stem cells by preventing NPC niche damage and promoting 
neuroregeneration pharmacologically. 
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APPENDIX A: Efficacy of wild-type and lpr NPC transplantation in EAE 
 
 
Introduction 
Based on results from in vitro experiments comparing wild-type (wt) and lpr 
NPCs (Chapter 3), I hypothesized that lpr NPCs would have enhanced efficacy 
when transplanted into mice with EAE. The enhanced differentiation of lpr NPCs 
into neuronal and oligo-progenitor lineages could result in increased terminal 
differentiation and integration of transplanted cells within the host CNS. 
Furthermore, the increased survival of lpr NPCs compared to wt NPCs in the 
absence of growth factors could result in enhanced immunoregulatory capacity of 
lpr NPCs in vivo. If a higher number of NPCs survive the transplantation process, 
perhaps this would lead to increased interactions between NPCs and immune 
cells allowing NPCs to decrease inflammation more efficiently. One or both of 
these mechanisms could contribute to enhanced clinical recovery in mice treated 
with lpr NPCs compared to wt. 
 
Methods 
 
NPC Isolation 
Brains were dissected from 4-day post-natal wt or lpr mouse pups (C57BL/6). 
NPC were extracted using NeuroCult® Enzymatic Dissociation Kit (Stem Cell 
Technologies) and plated in EGF and FGF containing medium. Neurospheres 
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were formed after 8-12 days in culture and the expression of Nestin (a putative 
stem cell marker) was confirmed using confocal microscopy. 
 
NPC Culture & Preparation 
Our wt and lpr NPC lines were transduced (lentivirus) with green fluorescent 
protein (GFP; courtesy Dr. Jeffery Spees, Director of the UVM Stem Cell Core). 
GFP+ Transfected NPCs expanded and were sorted to >85% purity using BD 
FACS Aria high-speed cell sorter (UVM COM Flow Cytometry Center).  
 
Sorted, GFP+ NPCs were plated in a monolayer on Poly-D lysine and laminin 
coated T-75 flasks (Nunc) in mouse-NPC complete media consisting of Gibco® 
Neural basal media, B-27 supplement, penicillin/streptomycin (10 mg/mL), L-
glutamine (29.20 mg/mL) EGF (10 ng/mL) and FGF (10 ng/mL). NPCs were 
allowed to grow to confluency for 3-5 days. At time of injection, NPCs were lifted 
from flasks using 0.05% trypsin (7 min at 37°C). Trypsin reaction was stopped 
using 20% FCS/Neural basal media. Cells were counted, rinsed, and 
resuspended in sterile phosphate buffered saline (PBS) at a concentration of 
1x106  cells/50 µL. 
 
Retro-orbital NPC Injections 
Mice were anesthetized using isoflourane (Webster Veterinary) before injected 
50 µL of the cell solution (1x106 cells ) into the retro-orbital sinus using a 27 ½ 
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gage syringe and then mice were observed until full motility returned. Mice 
receiving the vehicle control of sterile PBS were injected with the same volume of 
solution (50 µL) as the mice injected with cell solution. Cells were injected into 
mice immediately after suspension in sterile PBS and syringes were kept on ice 
in order to minimize the amount of cell death during the injection procedure. 
 
EAE Induction and Clinical Time Points 
Mice were first immunologically primed with a subcutaneous injection of 200 µg 
MOG (myelin oligodendrocyte glycoprotein)/CFA (complete Freud’s adjuvant). A 
second 200 µg MOG/CFA injection was given seven days later (considered “Day 
1” of the protocol). On Day 1, mice were also given a 200 ng PTX (pertussis 
toxin) intraperitoneal (IP) injection followed by a second 200 ng PTX injection 2 
days later. Mice were sacrificed at Day 21 (acute time point) or at Day 34 
(chronic time point). The induction and clinical protocol is summarized in Figure 
A-1.  
 
EAE Clinical Scoring 
Clinical scoring of EAE symptoms began on day 7 of the induction protocol and 
continued daily including the day of sacrifice. Mice generally started presenting 
with symptoms on days 9-11. The scoring criterion used in this study is a well-
established 5 point scoring scale where: 0 = no clinical symptoms, 1 = limpness 
in tail, 2 = hind limb ataxia, 3 = hind limb paralysis, 4 = hind limb paralysis with 
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incontinence and 5 = quadriplegia or paraplegia with clear forelimb weakness 
and moribund state. Scoring was conducted by a trained participant blinded to 
the treatment groups. 
 
Tissue Sample Harvesting 
Mice were given a 50 µL lethal dose of Nembutal® (Ovation) intraperitoneally. 
Intracardial perfusion was then performed using PBS followed by 10% formalin. 
Brains and spinal cords were then dissected and placed in 15 mL of 10% 
formalin and left to fix at room temperature for 24 hours. To remove fixative, 
samples were rinsed three times with PBS. Afterwards, samples were 
cryoprotected with sucrose gradients (tissue submerged in a 15% sucrose 
solution/0.2% azide in PBS on a rocker at 4C for 24 hours followed by a 30% 
sucrose solution on a rocker 4C for 24 hours). Samples were then frozen in 
NEG 50™ (Richard Allen Scientific) and stored in sealed plastic tubes at -80C 
until they were sliced. Samples were sliced using a cryostat at 20 µm section 
thickness and sections were stored and stained on microscope slides 
(Fisherbrand Superfrost Plus). 
Immunohistochemistry 
All sample slides were baked at 37°C for 15 min before the staining process 
began. Sample slides were stained for inflammation, after blocking in 10% goat 
serum/0.4% triton in PBS for 1 hour at room temperature, with an αCD-45 1° 
antibody (rat, Millipore 1:750) at 4°C for 24 hours. Slides were then rinsed with 
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PBS and a αRT-CY3 2° antibody (Jackson 1:500) was applied for 1 hour at room 
temperature. Before mounting, slides were stained with Hoecsht (1:2000). 
Samples stained for stem cell differentation markers were baked and blocked in 
the same fashion as those stained for inflammation. The primary antibodies used 
to stain for these markers included platelet-derived growth factor receptor-alpha 
(PDGFRα, rabbit, Santa Cruz 1:50 in 10%HS in PBS), beta III-tubulin (rabbit, 
Sigma 1:100 in 10% goat serum/0.4% triton in PBS) and glial fibrillary acidic 
protein (GFAP, rabbit, dako 1:250 in 10% goat serum/0.4% triton in PBS). After 
the primary was rinsed off with PBS after the 24 hour incubation at 4°C, αRb-CY3 
2 antibody (Jackson 1:500) was applied for 1 hour at room temperature and 
slides were stained with Hoecsht (1:2000) before mounting. 
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Figure A-1: EAE induction, treatment, and analysis timeline 
Experimental protocol summary illustrating induction procedures, treatment time-
point and clinico-pathological chronology. Mice were retro-orbitally injected with 
NPCs or PBS vehicle control at day 14, 1 week after 2nd MOG injection. At time 
of treatment (day 14), mice had exhibited clinical symptoms for 3-5 days. Mice 
were sacrificed either 7 days later (acute timepoint), or 20 days later (chronic 
timepoint) and brains were harvested for immunohistochemical analysis. Clincal 
scores for each mouse were recoreded over the entire experiment, starting at 
day 7). 
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Results 
 
 
 
 
Figure A-2:Retro-orbitally injected NPCs migrate to and reside with the CNS 
Representative image (combination of multiple 20x images) of periventricular 
brain section with GFP+ NPCs (green cells) in close association with infiltrating 
immune cells (red, CD45+). 
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Figure A-3: NPC treated mice show greater decrease in clinical scores 
post-injection than PBS treated mice 
(a) Mean clinical scores from each day after injection.  
(b) Mean clinical scores at the day of harvesting at the acute time point for lpr 
(n=11, p≤0.05), wt (n=10, p≤0.01) and PBS (n=9) treated mice. 
(c) Mean clinical scores at the day of harvesting at the chronic time point for 
lpr (n=5), wt (n=5) and PBS (n=5) treated mice.  
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Figure A-4: Recovery at the acute time point is greater in NPC treated mice 
than in PBS controls 
(a) Mean improvement in clinical score for lpr (n=11, p≤0.05) wt (n=10, p≤0.01) 
and PBS treated mice at the acute time point. Improvement in clinical score was 
determined by subtracting the clinical score at sacrifice from the clinical score at 
NPC injection. (b) Percent of mice showing recovery at acute time point for lpr 
(n=11, p≤0.05), wt (n=10) and PBS (n=9). A mouse was considered to be 
showing recovery if the clinical score at the time of sacrifice was less than the 
clinical score at the time of NPC injection. 
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Figure A-5: Periventricular brains and lumbar spines of mice treated with 
NPCs show a significant decrease in the amount of inflammation at the 
acute time point when compared to mice treated with PBS 
(a) Mean average object density of CD-45 positive cells in lpr (n=6, p≤0.05), wt 
(n=4, p≤0.05) and PBS determined using  Neurolucida image processing 
software. (b) Representative 20x images of lumbar spinal sections of lpr (left), wt 
(middle) and PBS (right) stained for CD-45 (red cells).  
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Table A-1: Clinco-pathological summary of EAE study 
 
Discussion 
To test weither lpr NPCs have superior clinical efficacy, we transplanted GFP-
labeled NPCs (either wt or lpr) into mice afflicted with EAE. Contrary to our 
original hypothesis, both lpr and wt NPCs resulted in similar reductions in clinical 
scores (Figure A-2 & A-3) and CNS inflammation (Figure A-4). These results 
could be the result of in vivo envitronmental factors that inhibit the differentiation 
of NPCs, despite their inherent capacity. Furthermore, if the primary mechanism 
for NPC-mediatied clinical benefit is via immunomodualtion, one would not 
expect to see differences between lpr and wt NPC efficacy since they posses the 
same abilities to immunoregulate (Chapter 4). Further studies are needed to 
determine: (1) factors that impede NPC differentiation in vivo and (2) whether 
methods to enhance NPC-mediated immunomodulation would positively affect 
clinical outcomes. 
**
*
*
*
Clinico-pathological Su ary of EAE Study
Data are mean numbers (SEM) from a total of n=3 independent experiments.
The mean disease score represents the scores of all mice in each group at the endpoint of each clinical period.
The cumulative disease score is the summation of all scores over the entire clinical period (20 days) in each group.
Inflammatory infiltrates are characterized by the mean optical density of CD45 positive cells in periventricular brain and lumbar spinal cord sections.
*p0.05 when compared to PBS injected controls.
**p0.01 when compared to PBS injected controls.

  

